



WORLD BANK



# ACEGID

African Centre of Excellence for Genomics of Infectious Disease  
*Redeemer's University, Nigeria*

**AFRICAN CENTRE OF EXCELLENCE FOR GENOMICS OF  
INFECTIOUS DISEASES (ACEGID)  
REDEEMER'S UNIVERSITY**

**SPECIAL PURPOSE REPORT AND FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 DECEMBER 2021**



SIAO · Accomplish More

(Chartered Accountants)  
18b Olu Holloway Road, Ikoyi, Lagos  
P.O. Box 55461, Falomo, Ikoyi, Lagos  
Tel: 01-4630871, 4630872  
Fax: 01-4630870  
Website: [www.siao-ng.com](http://www.siao-ng.com)  
E-mail: [enquiries@siao-ng.com](mailto:enquiries@siao-ng.com)

**AFRICAN CENTRE OF EXCELLENCE FOR GENOMICS OF INFECTIOUS DISEASES (ACEGID)**  
**Special Purpose Report and Financial Statements for the Year Ended 31 December, 2021**

<b>Table of Contents</b>	<b>Pages</b>
Special Purpose Report and Financial Statements	3
General Information	4
Report of the Centre's Officials	6
Statement of Centre's Officials' Responsibilities	14
Independent Auditors' Report	15
Statement of Financial Position	20
Statement of Income and Expenditure	21
Statement of Changes in Reserves	22
Statement of Cash flows	23
Significant Accounting Policies	24
Notes to the Financial Statements	40
Analysis of Expenses by Nature and Function	50
<b>Other National Disclosures</b>	52
Statement of Value Added	53
Financial Summary	54

**AFRICAN CENTRE OF EXCELLENCE FOR GENOMICS OF INFECTIOUS DISEASES (ACEGID)**  
**Special Purpose Report and Financial Statements for the Year Ended 31 December, 2021**

**Special Purpose Report and Financial Statements**

These Special Purpose Report and Financial Statements have been prepared exclusively for the ACE IMPACT grant provided by the World Bank for the prevention and eradication of infectious diseases such as malaria, lassa fever etc, which commenced on 1 April, 2015.

This new grant, tagged ACE IMPACT has been approved for another five years starting from 1 August, 2020. Therefore, these Special Purpose Report and Financial Statements are not the Annual Report and Financial Statements of the Centre, but Special Purpose Report and Financial Statements meant for monitoring the progress of the ACE IMPACT project for the year ended 31 December, 2021.

**AFRICAN CENTRE OF EXCELLENCE FOR GENOMICS OF INFECTIOUS DISEASES (ACEGID)**  
**Special Purpose Report and Financial Statements for the Year Ended 31 December, 2021**

**General Information**

**CENTRE'S OFFICIALS**

Prof. Christian Happi	.	Director
Prof. Folarin Onikepe	.	Deputy Director
Dr. Anise Happi	.	Deputy Director
Mrs. Mofoluso. O. Olutayo-David	.	Redeemer's University Bursar
Mr. Nosamiefan Iguosadolo	.	Programme Manager
Dr. Johnson Okolie	.	Project Manager
Mrs. Omowunmi-Hupe	.	Human Resource Manager
Mr. Idowu O. Afolabi	.	Project Accountant
Mrs. Banjo Adeyemi	.	Project Internal Auditor
Mrs. Lucy Osilaja	.	Procurement Officer
Mr. Abiodun Awolola	.	Finance Officer

**DIRECTORATE OF INTERNAL AUDIT**

Mrs. Kikelomo O. Akinlawon	.	Chief Internal Auditor
----------------------------	---	------------------------

**UNIVERSITY PRINCIPAL OFFICERS**

Professor Anthony E. Akinlo	.	Vice-Chancellor
Professor Adebola A.Adebileje	.	Deputy Vice Chancellor
Mr. Olukayode E. Akindele	.	Registrar
Mrs. Mofoluso. O. Olutayo-David	.	Bursar
Dr. Akinniyi A. Adeleke	.	Acting University Librarian

**INDEPENDENT AUDITORS**

SIAO (Chartered Accountants)  
 18b, Olu Holloway Road,  
 (Former Temple Road),  
 Off Alfred Rewane Road,  
 Ikoyi,  
 Lagos

**BANKERS**

Access Bank Plc  
 Zenith Bank Plc

**Host University**

Redeemer's University

**Postal Address**

P.M.B 230, Ede,  
 Osun State,  
 Nigeria.



**AFRICAN CENTRE OF EXCELLENCE FOR GENOMICS OF INFECTIOUS DISEASES (ACEGID)**  
**Special Purpose Report and Financial Statements for the Year Ended 31 December, 2021**

**General Information – (Cont'd)**

**Regional Partners**

<b>Names</b>	<b>Town/State</b>	<b>Country</b>
University of Ibadan,	Ibadan – Oyo	Nigeria
Irrua Specialist Teaching Hospital,	Irrua – Edo	Nigeria
Universite Cheikh Anta-Diop,	Dakar	Senegal
University of Sierra Leone,	Sierra Leone	Sierra Leone
Kenema Government Hospital,	Kenema	Sierra Leone
West Africa Genomics Research Networks		
University of Rwanda	Kigali	Rwanda
Stellenbosh University	Stellenbosh	South-Africa

**Global Partners**

<b>Names</b>	<b>Town/State</b>	<b>Country</b>
Harvard University,	Cambridge-Massachusetts	USA
Broad Institute,	Cambridge-Massachusetts	USA
Tulane University,	New Orleans-Louisiana	USA
National Institute of Allergy and Infectious Diseases	Maryland	USA
Viral Hemorrhagic Fever Consortium	Maryland	USA
University of Cambridge	Cambridge	UK
Walter Reed Army Institute of Research	Maryland	USA
The Wellcome Trust Limited	England	UK
University of California San Francisco	San Francisco	USA
University of Nebraska Medical Center	Omaha	USA
The Scripps Institutes	San Diego, California	USA
George Mason University	Virginia	USA
World Health Organization	Geneva	Switzerland
Africa Center for Disease Control	Addis-Ababa	Ethiopia
The Rockefeller Foundation	New-York	USA

**VISION**

To become an International Centre of Excellence with a global perspective that educates genomics leaders who will transform the World through high quality translational genomics-based research on health.

To constitute a strong force in support of the research on the study of humans and microbes to transform the clinical care, surveillance and understanding of infectious diseases.

**VALUES**

To attain the highest level of student learning, discovery and creative work in an atmosphere of inclusion, collaboration and partnership, guided by the highest standards of ethical conduct.

**AFRICAN CENTRE OF EXCELLENCE FOR GENOMICS OF INFECTIOUS DISEASES (ACEGID)**  
**Special Purpose Report and Financial Statements for the Year Ended 31 December, 2021**

**Report of the Centre's Officials**

**MISSION**

- To create, preserve and disseminate knowledge;
- To carry out each part of our mission at the highest level of excellence by guiding, facilitating and enhancing education and research quality, opportunities and experiences for all graduate students and researchers; and
- To educate the students for leadership and scholarship by creating a vibrant environment that is free of outside influences that transcend international boundaries and where creative, relevant, responsive, ethical and high quality translational genomics-based research on health in Africa is conducted.

**Background Information of the Centre**

The African Centre of Excellence for Genomics of Infectious Diseases ("ACEGID", "the Centre and the Project"), is located at Redeemer's University, Ede, Osun State in Nigeria and it is a World Bank funded collaborative research center. The Partners are: West African Academic and Medical Institutions, Redeemer's University, University of Ibadan, Irrua Specialist Teaching Hospital in Nigeria, University of Sierra Leone, Kenema Government Hospital in Sierra Leone and Universite Cheikh Anta-Diop de Dakar in Senegal.

The Centre was established in September 2013 upon approval of the World Bank of the proposed genomics research activities forwarded by the Redeemer's University Management.

ACEGID has a mandate to build capacity in the field of genomics in young African scientists and use, identify and characterize pathogens of unknown origin using microbial metagenomics. Ultimately the Project aims to translate the research outcome to products that can be deployed to the field in order to contribute to the control, management and elimination of infectious diseases in the continent.

**Primary Thematic Discipline of Centre**

The Centre's primary thematic discipline for the year under review are Infectious Diseases such as Malaria, Lassa, Ebola, HIV, Yellow fever, Monkey pox and Covid -19. The Centre is also increasing focus on human genomics and non-communicable diseases.

**Key Objectives and Expected Outcomes**

**Overarching Goal:**

To create a vibrant academic and research environment that is free of outside influences, one that transcends national boundaries and ensures the conduct of relevant, responsive, ethical and high quality translational genomics-based research on health in Africa.



**AFRICAN CENTRE OF EXCELLENCE FOR GENOMICS OF INFECTIOUS DISEASES (ACEGID)**  
**Special Purpose Report and Financial Statements for the Year Ended 31 December, 2021**

**Report of the Centre Officials – (Cont'd)**

**Specific Aims**

- Develop African research capacity in genomics by building well-trained scientists;
- Empower African researchers to utilize genomics-based tools towards the control and elimination of infectious diseases;
- Create genomics curricula to support and promote cutting-edge genomics-based research;
- Engage communities in prevention efforts and public health education;
- Use field-deployed and state-of-the-art genomic technology to identify pathogens driving febrile illness; and
- Create a foundation for African scientists to carry out tractable and important genetic research projects throughout in the Continent.

**Result for the year ended 31 December, 2021:**

The summary of the operating result from utilization of grants and other funds received during the year ended 31 December, 2021 is as stated below:

	<b>1 January – 31 December, 2021 (12 - Month) ₦</b>	<b>1 August – 31 December, 2020 (5 - month) ₦</b>
Grants and Other Incomes	<b>6,092,577,996</b>	1,422,077,958
<b>Less: Administrative and other Expenses</b>	<b>(2,938,060,446)</b>	(1,015,175,000)
Surplus for the year/period	<b>3,154,517,550</b>	406,902,958

**Property, Plant and Equipment**

Information relating to changes in property, plant and equipment is shown in **note 6** to the Financial Statements. The Centre's Officials believe that the market value of the Centre's property, plant and equipment is not less than the carrying value shown in these Special Purpose Report and Financial Statements.

**Events after the Reporting Date**

The Centre's Officials are not aware of an event subsequent to 31 December, 2021 which is likely to have a material effect on the financial information contained in these Special Purpose Report and Financial Statements and/or may have affected the true and fair view of the Centre's state of affairs as at that date.

**AFRICAN CENTRE OF EXCELLENCE FOR GENOMICS OF INFECTIOUS DISEASES (ACEGID)**  
**Special Purpose Report and Financial Statements for the Year Ended 31 December, 2021**

**Report of the Centre Officials – (Cont'd)**

**Human Resources Policies and Other Matters**

The Centre recognizes that its human resources are very valuable assets. Consequently, the human resources policies of the Centre are to ensure that the Centre continues to place premium on its human capital development arising from the fact that this would ensure improvement, efficiency and prompt response to finding solutions to infectious diseases in the African continent.

The Management holds periodic meetings with the employees in order to brief them on current related issues and exchange ideas that are beneficial to both parties. In addition, Management communicates issues to employees regularly through email, circulars and newsletters.

**Employment of Physically Challenged Persons**

It is the Centre's policy that there should be no discrimination in considering applications for employment including application by those that are physically challenged persons. All employees whether physically challenged or not are given equal opportunities to develop their experience and knowledge in the Centre. As at 31 December, 2021, no physical challenged person was employed at the Centre.

**Employment and Employee Developments**

The Centre reviews its employment policy in line with the needs in the field of research and teaching related activities. Careful recruiting is undertaken to ensure that potential high performers are attracted and retained. Local and overseas training and development programmes are organized to meet the needs of the Centre's approach to research and modernization of teaching techniques.

**Equal Employment Opportunity and Diversity**

Subject to applicable laws, the Centre recruits, hires, trains, promotes, disciplines and provides other conditions of employment without regard to a person's race, colour, religion, sex, age, national origin, disability or other classifications protected under law.

**Health and Safety of the Centre Employment**

Health and safety regulations are in force within the Centre's premises and employees are aware of existing regulations. The Centre appreciates the value of a safe work environment and therefore embarks on periodic assessments to ensure compliance and safety rules. With the advent of the novel coronavirus (Covid – 19) confirmed by World Health Organization in December 2019, employees safety measures were mobilized including the provision of hand sanitizers, nose masks, activation of hand wash points and strict monitoring of social distancing practices.



**AFRICAN CENTRE OF EXCELLENCE FOR GENOMICS OF INFECTIOUS DISEASES (ACEGID)**  
**Special Purpose Report and Financial Statements for the Year Ended 31 December, 2021**

**Report of the Centre Officials – (Cont'd)**

**Admission into the Centre**

In line with the Centre's primary objectives to develop a critical mass of well-trained Genomics Scientists in the African Continent, student enrolment as at 31 December, 2021 were:

<b>Programme</b>	<b>1 January – 31 December, 2021 (12- month)</b>	<b>1 August – 31 December, 2020 (5 month)</b>
Master Degree Level	7	20
PhD. Degree Level	47	11

Admission of students into the Centre was processed through the Redeemer's University, Ede – Osun State as the host Institution. The number of people trained by the Centre from 2013 - 2021 is over 1,300.

**AFRICAN CENTRE OF EXCELLENCE FOR GENOMICS OF INFECTIOUS DISEASES (ACEGID)**  
**Special Purpose Report and Financial Statements for the Year Ended 31 December, 2021**

**Report of the Centre Officials – (Cont'd)**

**Information about the Centre Sponsors**

The Centre benefited from the sponsorship and/or partnership of the following organizations, bodies and councils through award of grants for research purposes in the field of Genomics of Infectious Diseases. The sponsors and their areas of interests are as stated below:

NAME OF SPONSORS	PROJECT	DURATION
World Bank – (Through the Association of African Universities (AAU))	Africa Centre of Excellence for Genomics of Infectious Diseases.	December 31, 2019 to November 2025
National Institutes of Health - H3Africa	Genomic Characterization and Surveillance of Microbial Threats in West Africa.	July 2017 – June 2022.
Biotechnology and Biological Sciences Research Council (BBSRC)	One Health and Accelerating Vaccines for Ebola and Lassa (OVEL).	May 01, 2018 to March 31 <sup>st</sup> , 2021
Joint West Africa Research Group (JWARG)	Infectious Disease Surveillance Studying to include: Malaria, Yellow Fever, Lassa Fever and Dengue Fever.	2018 – 2023
The Wellcome Trust Limited	Lassa outbreak response, early intervention and community response capacity in Ondo, Edo and Ebonyi States in Nigeria.	2019 – 2020
The ELMA Relief Foundation	Pandemic, early detection networks	2020 – 2025
FAST GRANT	Covid – 19 Related Science - ACEGID	2020 - 2022
Africa Academy of Sciences	Covid-19 R&D in Africa	2020-2022
Africa CDC/ASLM	Africa Pathogen Genomic Initiative	2021-2022
Rockefeller Foundation	Capacity Building for Pathogen Genomics in Africa	2021-2023



**AFRICAN CENTRE OF EXCELLENCE FOR GENOMICS OF INFECTIOUS DISEASES (ACEGID)**  
**Special Purpose Report and Financial Statements for the Year Ended 31 December, 2021**

**Report of the Centre Officials – (Cont'd)**

**Major Accomplishments to Date:**

- Accurate diagnosis of the first case of Ebola in Sierra Leone and Nigeria in the 2014 EVD outbreak;
- Sequenced approximately 250 Ebola virus genomes and made available in the databank;
- Sequenced over 1,000 Lassa fever virus genomes, thus generating the largest catalogue of the virus in the world;
- Provided tools and training for disease diagnosis, sequencing and bioinformatics;
- Developed the capacity and provided facilities to study a BL4 pathogen in rural field settings (Nigeria and Sierra Leone);
- Developed Ebola virus rapid diagnostics test (RDT) for rapid diagnosis of the disease in 10mins;
- Developed a new pan – Lassa fever rapid diagnostics test kit for diagnosis of the -disease in 10mins;
- Discovered 2-novel highly divergent rhabdovirus in Ekpoma, Nigeria;
- Used clinical sequencing to uncover the origin and evolution of Lassa virus;
- Discovered neutralizing monoclonal antibodies that target epitopes on Lassa virus glycoproteins giving potential for immunotherapeutic in Lassa fever;
- Participated in the 1,000 genome project for the development of global reference for human genetic variation;
- Received the 1st prize in the Life Sciences and Medicine category at the 6th Nigerian Universities Research and Development fair;
- The Center received the 2021 Gold Medal Prize of the Nigerian Academy of Science;
- Trained approximately 1,300 young African scientists in the field of Genomics and Bioinformatics between 2014 and 31 December, 2021;
- The Center reconfirmed the first Covid-19 case in Nigeria and sequenced the first SARS-Cov-2 in Africa; and has supported Nigerian Government Covid-19 response through the sequencing of over 4,000 SARS-CoV genomes in Nigeria alone;
- The Center has tested more than 150,000 Covid-19 samples in Nigeria;
- Trained researchers and scientists from 32 African countries on next generation sequencing. Therefore, supporting their national responses to the pandemic.
- The Centre is now a reference Centre for Infectious Diseases research for the World Health Organization (WHO) and the Africa Center for Disease Control (AfCDC).



**AFRICAN CENTRE OF EXCELLENCE FOR GENOMICS OF INFECTIOUS DISEASES (ACEGID)**  
**Special Purpose Report and Financial Statements for the Year Ended 31 December, 2021**

**Report of the Centre Officials – (Cont'd)**

**Overall Projects Achievements**

Following the award of the project in 2013 by the World Bank and subsequent signature of the performance agreement contract between Redeemer's University and the National Universities Commission in February 2015, ACEGID has been engaged in research and academic activities that have highly impacted health development in the West Africa Sub-region, as well as significantly improved the visibility of Redeemer's University and other West African collaborating institutions in the Committee of Universities in Africa and the World.

**Impact of COVID – 19 on the Centre**

Nigeria recorded her first index case of Coronavirus (Covid – 19) on Friday 27 February, 2020, as pronounced by the National Centre for Disease Control (NCDC). On 11 March, 2020, the World Health Organization declared the Covid – 19 outbreak a pandemic and most governments have taken restrictive measures to contain its further spread by introducing lockdowns, closures of borders and travel restrictions which has affected the free movement of people and goods.

The impact of Covid - 19 on the Centre's operations were as follows:

- Increasing the level of testing of sample cases;
- Restricted movement of staff with limited activities performed remotely;
- Stoppage of research related activities;
- Involvement of our regional partners in the Centre was limited; and
- Academic activities were suspended for the period.

**Going Concern**

The Centre Officials believe that it has adequate financial resources in form of grants from various donors to continue in operation for the foreseeable future and accordingly these Special Purpose Report and Financial Statements have been prepared on a going concern basis. The Centre's Officials have satisfied themselves that the Centre is in a sound financial position and that it has access to sufficient research related grants and other facilities needed to meet its expenditures and foreseeable cash requirements on research into genomics of infectious diseases in Africa. The Centre's Officials are not aware of any new material changes that may adversely impact the Centre. The Centre's Officials are also not aware of any material non-compliance with statutory or regulatory requirements or of any pending changes to legislation which may affect the Centre.

The Centre's Officials are of the opinion that continuous access to financial grant from the World Bank and other donors will also contribute significantly to the growth and stability of the Centre toward the achievement of its aims and objectives.

**Format of Special Purpose Report and Financial Statements**

These Special Purpose Report and Financial Statements of African Centre of Excellence for Genomics of Infectious Diseases have been prepared in accordance with the reporting and presentation requirements of International Financial Reporting Standards (IFRSs) issued by International Accounting Standards Board (IASB) as adopted by the Financial Reporting Council of Nigeria (FRC).

These Special Purpose Report and Financial Statements show the utilization of the World Bank ACE IMPACT and other grants over the past seventeen months for the research and academic activities (teaching) in genomics of infectious diseases in the Africa continent. This is in compliance with the signed agreement among World Bank, National University Commission (NUC) and Redeemer's University in September 2015.



**Report of the Centre Officials – (Cont'd)**

**Independent Auditor's**

Messrs. SIAO (Chartered Accountants), having satisfied the relevant corporate governance rules on their tenure in office have indicated their willingness to continue in office as auditors to the Centre.

**BY ORDER OF THE CENTRE'S SECRETARY**



**Prof. (Mrs.) Onikepe Folarin**

**AFRICAN CENTRE OF EXCELLENCE FOR GENOMICS OF INFECTIOUS DISEASES (ACEGID)**

**Special Purpose Report and Financial Statements for the Year Ended 31 December, 2021.**

**STATEMENT OF CENTRE'S OFFICIALS' RESPONSIBILITIES**

The Centre's Officials are responsible for the preparation of these Special Purpose Report and Financial Statements which give a true and fair view in compliance with the International Financial Reporting Standards (IFRSs).

The Centre's Officials are obliged to ensure that:

- Proper accounting records are maintained on the disbursement of the fund on research;
- Internal control measures are instituted to safeguard the assets;
- Actions are taken to prevent and detect fraud and other irregularities in funds utilization;
- Applicable accounting standards are followed for financial reporting;
- Suitable accounting policies are adopted and consistently applied throughout the period;
- Judgments and estimates made are reasonable and prudent, and
- The going-concern basis is used, unless it is inappropriate to presume that the Centre will continue in operation.

The Centre's Officials are responsible for keeping proper accounting records which disclose, with reasonable accuracy at any time, the financial position of the Centre.


The Centre's Officials accept responsibilities for these Report and Financial Statements, which have been prepared in line with the International Financial Reporting Standards (IFRSs), and signed agreement between Redeemer's University, World Bank and other donors on the research grants released to the Centre.

The Centre's Officials further accept responsibility for the maintenance of accounting records that may be relied upon in the preparation of these Special Purpose Report and Financial Statements as well as adequate systems of financial control.

The Centre's Officials have made an assessment of the Centre's ability to continue as a going concern and have no reasons to believe that the Centre will not continue as a going concern in the year ahead.

**Signed on behalf of the Centre Officials**

  
**Prof. Christian Happi**  
Centre Director

  
**Mrs. Mofoluso O. Olutayo-David**  
Bursar, Redeemer's University

## Independent Auditors' Report

### Report of the Auditors to the stakeholders of **AFRICAN CENTRE OF EXCELLENCE FOR GENOMICS OF INFECTIOUS DISEASES (ACEGID)**

#### Opinion

We have audited the accompanying Special Purpose Report and Financial Statements of **African Centre of Excellence for Genomics of Infectious Diseases (ACEGID)**, which comprise the Statement of Financial Position as at December 31 December, 2021, the Statement of Income and Expenditure, Statement of Changes in Reserves and Cash flows Statement for the year then ended, which have been prepared on the basis of the summary of the significant accounting policies on **pages 23 to 38** and other explanatory notes to the Special Purpose Report and Financial Statements, as set out on **pages 39 to 49**.

In our opinion, the Special Purpose Report and Financial Statements present fairly, in all material respects, the financial position of **African Centre of Excellence for Genomics of Infectious Diseases (ACEGID)**, and its financial performance for the year ended 31 December, 2021 in accordance with International Financial Reporting Standards (IFRSs) issued by the International Accounting Standards Board.

#### Basis for Opinion

We conducted our audit in accordance with International Standards on Auditing (ISAs) issued by the International Federation of Accountants (IFAC). Our responsibilities under those standards are further described in the Auditors' Responsibilities for the audit of the Centre's Special Purpose Report and Financial Statements as part of this report. We are independent of the Centre in accordance with the Institute of Chartered Accountants of Nigeria (ICAN) ethical requirements together with International Ethics Standards Board for Accountants' Code of Ethics for Professional Accountants (IESBA Code) that are relevant to our audit of the Special Purpose Report and Financial Statements.

Therefore, we believe that the information, explanation and audit evidence we have obtained are sufficient and appropriate to provide a basis for our audit opinion.



## Emphasis of Matter

We draw attention to International Accounting Standards – IAS 34, paragraph 20: “Interim Financial Reporting” for an entity as regards comparative figures. Based on the above for compliance purpose, the comparative numbers presented for the five - month period that ended 31 December, 2020 have been audited.

## Key Audit Matters

The Key Audit Matters are those matters that in our professional judgment were of most significance in our audit of these Special Purpose Report and Financial Statements of the year ended 31 December, 2021. These matters were addressed in the context of our audit of the Centre’s Special Purpose Report and Financial Statements as a whole and in forming our opinion thereon, we do not provide a separate opinion on these matters

### Revenue recognition for donations and research grants

The Centre reported **N6.09billion** as income in the year from donations, research grants and internally generated revenue. Research grants received from various donors accounted for 63% of the total income recognized during the year that ended 31 December, 2021. Other income streams such as foreign exchange gain, tuition fee and internally generated revenue (IGR) contributed about 37% to the Centre revenue profile.

### How our audit addressed the Key Audit Matters.

In evaluating the appropriateness, completeness, classification and disclosures of the research grants received by the Centre’s Officials as reported in these Special Purpose Report and Financial Statements, we performed the following review.

- We evaluated and tested the accounting policy for income recognition on research grants and donations to ensure that this is consistent with the requirements of accounting standards;
- We obtained and reviewed evidence of performance obligation as agreed with the donors before the disbursement of funds;
- We performed detailed testing of the research grants received from the donors for completeness and disclosure;
- We traced the receipts of the grants to the Centre’s main bank accounts dedicated for that purpose;
- We obtained confirmation from the Centre’s banks for disclosure purpose; and
- No exceptions were noted from our work.

We have satisfied ourselves that the treatment of the research grants and donations are appropriate for disclosures in these Special Purpose Report and Financial Statements.



### **Other Information in the Audit Report**

The Centre's Officials are responsible for the other information. The other information comprises the Centre officials' Report which we obtained prior to the date of this special purpose report. Other information does not include the Special Purpose Report and Financial Statements and our auditors' report thereon. Our opinion on these Special Purpose Report and Financial Statements does not cover the other information and we do not express an audit opinion or any form of assurance on the conclusion thereon.

In connection with our audit of the Special Purpose Report and Financial Statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the Special Purpose Report and Financial Statements or our knowledge obtained in the audit, or otherwise appear to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information; we are required to report that fact. We have nothing to report in this regard.

### **Responsibilities of the Centre Officials for the Special Purpose Report and Financial Statements**

The Centre's Officials are responsible for the preparation and fair presentation of the Special Purpose Report and Financial Statements in accordance with International Financial Reporting Standards and the requirements of the Financial Reporting Council of Nigeria Act No. 6, 2011, and for such internal control as the Centre's Officials determine is necessary to enable the preparation of Special Purpose Report and Financial Statements that are free from material misstatement, whether due to fraud or error.

In preparing the Centre's Special Purpose Report and Financial Statements, Centre Officials are responsible for assessing the Centre's ability to continue as a going concern, disclosing as applicable, matters related to going concern and using the going concern basis of accounting unless the Centre's Officials either intend to liquidate the Centre or to cease operation or have no realistic alternative to do so.

### **Auditors' Responsibilities for the Audit of the Special Purpose Report and Financial Statements**

Our objectives are to obtain reasonable assurance about whether these Special Purpose Report and Financial Statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with International Standards on Auditing will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Special Purpose Report and Financial Statements.

As part of an audit in accordance with International Standards on Auditing (ISA), we exercise professional judgement and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of these Special Purpose Report and Financial Statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control;
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Centre's internal control;
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Centre's Officials;
- Conclude on the appropriateness of the Centre's Officials use of the going concern basis of accounting and based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Centre ability to continue into the future. If we conclude that a material uncertainty exists, we are required to draw attention in our auditors' report to the related disclosures in these Special Purpose Report and Financial Statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditors' report. However, future events or conditions may cause the Centre to cease to continue as a going concern; and
- Evaluate the overall presentation, structure and content of the Centre's Special Purpose Report and Financial Statements, including the disclosures, and whether the Centre's Special Purpose Report and Financial Statements represent the underlying transactions and events in a manner that achieves fair presentation.

We obtain sufficient and appropriate audit evidence regarding the financial information of the Centre to express an opinion in the Centre's Special Purpose Report and Financial Statements. We are responsible for the direction, supervision and performance of the audit and we remain solely responsible for our audit opinion.

We communicate with the Audit and Risk Management Committee of the Host University – Redeemer's University, Ede, regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide the Audit and Risk Management Committee and Centre's Officials with a statement that we have complied with relevant ethical requirements regarding independence, and to



communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with the Audit and Risk Management Committee and Centre's Officials, we determine those matter that was of most significance in the audit of the Special Purpose Report and Financial Statements for the year ended 31 December, 2021 and are therefore the key audit matters. We describe these matters in our auditors' report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the benefits derivable by the public from such communication.

### Report on other legal and regulatory requirements

In accordance with the Financial Reporting Council of Nigeria Act 2011 and the Companies and Allied Matters Act, 2020:

- I. We have obtained all the information and explanation which to the best of our knowledge and belief were necessary for the purpose of the audit.
- II. The Centre has kept proper books of account, so far as appears from our examination of those books.
- III. The Centre's statement of financial position and the statement of income and expenditure are in agreement with the books of account and returns.

A handwritten signature in blue ink, appearing to read 'Abiodun Ariyibi', is written over a horizontal line.

**Abiodun Ariyibi**

**FRC/2013/ICAN/00000001548**

**For: SIAO (Chartered Accountants)**

Lagos, Nigeria.

Date: 29th June 2022



**AFRICAN CENTRE OF EXCELLENCE FOR GENOMICS OF INFECTIOUS DISEASES (ACEGID)**  
**Special Purpose Report and Financial Statements for the Year Ended 31 December, 2021**


**STATEMENT OF FINANCIAL POSITION**

**AS AT 31 DECEMBER, 2021**

		31/12/2021	31/12/2020
	Notes	=N=	=N=
<b>NON - CURRENT ASSET</b>			
Property Plant and Equipment	6	3,296,717,558	2,461,078,524
Intangible Asset	7	7,197,337	11,506,721
Prepayment	11	2,871,123	3,100,000
		<u>3,306,786,018</u>	<u>2,475,685,245</u>
<b>CURRENT ASSETS</b>			
Cash and Cash Equivalents	8	4,960,946,468	2,570,397,481
Receivables	9	791,574,624	729,073,716
Other Receivables	10	33,875,556	4,897,639
Prepayment	11	1,200,000	1,200,000
		<u>5,787,596,648</u>	<u>3,305,568,836</u>
<b>TOTAL ASSETS</b>		<u><u>9,094,382,666</u></u>	<u><u>5,781,254,081</u></u>
<b>RESERVES AND LIABILITIES:</b>			
Reserves	12	8,036,011,266	4,881,493,716
<b>CURRENT LIABILITY</b>			
Other Payables	13	<u>1,058,371,400</u>	<u>899,760,365</u>
<b>TOTAL RESERVES AND LIABILITIES</b>		<u><u>9,094,382,666</u></u>	<u><u>5,781,254,081</u></u>

The Special Purpose Report and Financial statements were approved by the Centre Officials on 29/6/22 and were signed on its behalf by:

  
 .....  
 Prof. Christian Happi  
 Centre Director

  
 .....  
 Mrs. Mofoluso O. Olutayo-David  
 Bursar, Redeemer's University

The significant accounting policies on pages 24 to 39 and the accompanying explanatory notes on pages 40 to 49 form an integral part of these Special Purpose Report and Financial Statements.



**AFRICAN CENTRE OF EXCELLENCE FOR GENOMICS OF INFECTIOUS DISEASES (ACEGID)**  
**Special Purpose Report and Financial Statements for the Year Ended 31 December, 2021**

**STATEMENT OF INCOME AND EXPENDITURE**  
**FOR THE YEAR ENDED 31 DECEMBER, 2021**

	Notes	31/12/2021 (12 Months) =N=	31/12/2020 (5 Months) =N=
<b>INCOME</b>			
Research Grants Received	14	3,813,607,170	1,092,181,395
Interest income	15	460,255	61,218
Registration and tuition fees	16	-	1,250,000
Exchange gain (Unrealized)	17	2,054,343,175	244,404,549
Other income	18	224,167,396	84,180,796
		<u>6,092,577,996</u>	<u>1,422,077,958</u>
<b>EXPENDITURE:</b>			
Salaries and Wages	19	884,005,136	336,123,450
Publication in Journals		6,390,296	1,326,250
Seminars and Courses		4,618,889	1,922,419
Printing and Stationery		9,138,046	1,886,300
Office Consumables		-	13,600
I.T Expenses		15,078,142	1,406,520
Cleaning Charges		2,968,219	928,730
Electricity & Lighting		873,800	50,000
Telephone and Postages		3,194,352	1,104,993
Transport and Travels Expenses		38,249,514	7,462,679
Entertainment Expenses		1,930,813	1,760,690
Bank Charges		8,035,190	3,478,216
Repairs and Maintenance		16,777,709	5,823,912
Motor Vehicle Running		7,471,708	1,541,436
Laboratory Consumables	27	1,180,181,964	312,135,578
Reimbursable Expenses - Audit		500,000	388,750
Depreciation and Amortisation- PPE	6&7	262,237,754	81,844,691
Covid-19 Test Expenses		2,730,400	618,000
Insurance Expenses		-	242,946
Generator Running Expenses		5,882,000	920,000
Subscription		2,050,345	7,590,000
Subaward	27	189,379,238	205,312,119
Hotel Expenses		10,188,475	933,319
Rent Expenses		1,452,667	500,000
Vehicle Leasing Expenses	27	32,772,800	24,288,000
Public Relations/Publicity		35,000	-
Gift & Donation Expenses		5,860,000	-
Other Conference & Airfare Expenses		245,870	-
Sample - Transport		120,000	-
Other Medical Expenses		573,342	-
Exchange Rate Variance		751,515	-
Genomics Foundational Training Exp.		16,477,698	-
Africa Centre of Excellence Meeting & Workshop		800,000	-
Other Research Expenses		28,340,103	-
Facilities and Administrative		198,749,461	15,572,403
		<u>2,938,060,446</u>	<u>1,015,175,000</u>
<b>Surplus of income over expenditure</b>		<u><b>3,154,517,550</b></u>	<u><b>406,902,958</b></u>

The significant accounting policies on pages 24 to 39 and the accompanying explanatory notes on pages 40 to 49 form an integral part of these Special Purpose Report and Financial Statements.

**AFRICAN CENTRE OF EXCELLENCE FOR GENOMICS OF INFECTIOUS DISEASES (ACEGID)**  
**Special Purpose Report and Financial Statements for the Year Ended 31 December, 2021**

**STATEMENT OF CHANGES IN RESERVES**

**AS AT 31 DECEMBER, 2021**

**Unrestricted Reserves**

As at 1 August, 2020		<b>4,474,590,758</b>
Surplus for the period (5 months)	<b>12</b>	<b>406,902,958</b>
<b>As at 31 December, 2020</b>		<b>4,881,493,716</b>
As at 1 January, 2021		<b>4,881,493,716</b>
Surplus for the year	<b>12</b>	<b>3,154,517,550</b>
<b>As at 31 December, 2021</b>		<b>8,036,011,266</b>

The significant accounting policies on pages 24 to 39 and the accompanying explanatory notes on pages 40 to 49 form an integral part of these Special Purpose Report and Financial Statements.



**AFRICAN CENTRE OF EXCELLENCE FOR GENOMICS OF INFECTIOUS DISEASES (ACEGID)**  
**Special Purpose Report and Financial Statements for the Year Ended 31 December, 2021**

**STATEMENT OF CASHFLOWS**  
**FOR THE YEAR ENDED 31 DECEMBER, 2021**

	Notes	31/12/2021 (12 Months) =N=	31/12/2020 (5 Months) =N=
<b>CASHFLOWS FROM OPERATING ACTIVITIES</b>			
Surplus for the year		<b>3,154,517,550</b>	406,902,958
<b>Adjustments for non-cash items:</b>			
Depreciation - PPE	6	<b>257,928,370</b>	80,421,966
Gain on disposal		<b>3,063,600</b>	-
Amortization - Intangible Asset	7	<b>4,309,384</b>	1,422,725
Interest income	15	<b>(460,255)</b>	(61,218)
Exchange gain (Unrealized)		<b>2,054,343,175</b>	244,404,549
<b>Operating surplus before changes in working capital</b>		<b>5,473,701,825</b>	733,090,980
<b>Changes in Working Capital</b>			
Changes in other payables	13	<b>158,611,036</b>	302,271,548
Changes in receivables	9	<b>(91,478,825)</b>	(190,309,081)
Changes in prepayment	11	<b>228,877</b>	742,946
<b>Net Cash Inflows from Operating Activities</b>		<b>5,541,062,913</b>	845,796,393
<b>Investing Activities</b>			
Purchase of Property Plant and Equipment	6	<b>(1,108,885,405)</b>	(497,958,563)
Purchase of Intangible Asset	7	<b>-</b>	(3,999,999)
Proceeds from Disposal		<b>12,254,400</b>	-
Interest received	15	<b>460,255</b>	61,218
<b>Net Cash (Outflows) from Investing Activities</b>		<b>(1,096,170,750)</b>	(501,897,344)
Net increase in cash and cash equivalents for the year		<b>4,444,892,163</b>	343,899,048
Cash and cash equivalents as at 1 January,		<b>2,570,397,481</b>	2,470,902,982
Exchange gain (Unrealized)		<b>(2,054,343,175)</b>	(244,404,549)
<b>Cash and cash equivalents as at 31 December,</b>	<b>8</b>	<b>4,960,946,468</b>	2,570,397,481

The significant accounting policies on pages 24 to 39 and the accompanying explanatory notes on pages 40 to 49 form an integral part of these Special Purpose Report and Financial Statements.

**AFRICAN CENTRE OF EXCELLENCE FOR GENOMICS OF INFECTIOUS DISEASES (ACEGID)**  
**Special Purpose Report and Financial Statements for the Year Ended 31 December, 2021**

**CENTRE INFORMATION**

**1.0 The Centre**

The African Centre of Excellence for Genomics of Infectious Diseases “ACEGID”, is located at Redeemer’s University, Ede, Osun State in Nigeria and it is a World Bank funded collaborative research center. The Partners are West African Academic and Medical Institutions, Redeemer’s University, University of Ibadan, Irrua Specialist Teaching Hospital in Nigeria, University of Sierra Leone, Kenema Government Hospital in Sierra Leone and Universite, Cheikh Anta-Diop de Dakar in Senegal.

The Centre was established in September 2013 upon approval of the World Bank of the proposed genomics research activities forwarded by the Redeemer’s University Management.

**1.1 Principal Activities**

The principal activities of the Centre are that of providing research and academic training in areas of genomics infectious diseases in the Africa Continent. ACEGID has a mandate to build capacity in the field of genomics in young African scientists and use, identify and characterize pathogens of unknown origin using microbial metagenomics. Ultimately the Project aims to translate the research outcome to products that can be deployed to the field in order to contribute to the control, manage and eliminate infectious diseases in the continent. However, each of the sponsors is expected to renew the life span of their projects in line with international benchmark for research related activities.

**1.2 Reporting Period**

These Special Purpose Report and Financial Statements cover the financial period from 1 January to 31 December, 2021 with comparative period from 1 August, 2020 to 31 December, 2020.

**1.3 Going Concern**

The Centre has consistently been awarded grants from various donors on its core principal activities relating to research activities on infectious diseases such as Ebola, Lassa and other infectious viruses. The Centre’s Officials believe that there is no intention or threat from any party to curtail significantly its line of activities in the foreseeable future. These Special Purpose Report and Financial Statements are prepared on a going concern basis.

**2.0 Significant Accounting Policies**

**2.1 Basis of Presentation and Compliance**

The Centre's Special Purpose Report and Financial Statements for the year ended 31 December, 2021 are prepared and presented in accordance with, and comply with International Financial Reporting Standards (IFRSs) and International Financial Reporting Interpretation Committee (IFRIC) interpretations issued and effective for the year presented. These Special Purpose Report and Financial Statements are not the annual report and Financial Statements of the Centre but a Special Purpose Report and Financial Statements meant for the use of the donors.



**AFRICAN CENTRE OF EXCELLENCE FOR GENOMICS OF INFECTIOUS DISEASES (ACEGID)**  
**Special Purpose Report and Financial Statements for the Year Ended 31 December, 2021**

**Significant Accounting Policies – (Cont'd)**

**2.1.1 Composition of Special Purpose Report and Financial Statements**

The Centre Special Purpose Report and Financial Statements comprise:

- Statement of Financial Position;
- Statement of Income and Expenditure;
- Statement of Changes in Reserves;
- Statement of Cashflows;
- Accounting policies and
- Notes to the Special Purpose Report and Financial Statements.

**2.1.2 Statement of Compliance**

These Special Purpose Report and Financial Statements for the year ended 31 December, 2021 have been prepared in accordance with International Accounting Standards (IAS) and International Financial Reporting Standards (IFRSs) as issued by the International Accounting Standards Board (IASB), that are effective as at 31 December, 2021.

**2.1.3 Functional and Presentation Currency**

The Special Purpose Report and Financial Statements are presented in Naira, which is the Centre's presentational currency. The figures shown in the Special Purpose Report and Financial Statements are stated to the nearest Naira. The accounting policies set out below have been applied in these Special Purpose Report and Financial Statements unless otherwise indicated.

**2.1.4 Translation of Foreign Currencies**

Foreign currency transactions are recorded on initial recognition in Naira by translating the foreign currency amount at the spot exchange rate between the functional currency and foreign currency at the date of the translation.

At the end of the reporting period:

- Foreign currency monetary items are translated using the applicable closing foreign exchange rates.
- Non-monetary items that are carried at historical cost translated at the exchange rate at the date of translation.

Exchange differences arising on the settlement of monetary items or on translating monetary items are recognized in the statement of income and expenditure in the year in which they arise.

**2.2 Basis of Measurement**

The Special Purpose Report and Financial Statements have been prepared under the historical cost convention, unless mentioned otherwise in the accounting policies and notes to the Special Purpose Report and Financial Statements.

**AFRICAN CENTRE OF EXCELLENCE FOR GENOMICS OF INFECTIOUS DISEASES (ACEGID)**  
**Special Purpose Report and Financial Statements for the Year Ended 31 December, 2021**

**Significant Accounting Policies – (Cont'd)**

**2.3 Critical Accounting Judgements, Estimates, and Assumptions**

Management is required to adopt those accounting policies most appropriate to the circumstances for the purposes of presenting fairly the Centre's financial position, financial performance, and cash flows. The preparation of the Centre's Special Purpose Report and Financial Statements require management to make judgements, estimates, and assumptions that affect the application of policies and reported amounts of assets and liabilities, income and expenses.

These judgements, estimates, and associated assumptions are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. The resulting accounting estimates will, by definition, seldom equal the related actual results.

Management considers the areas set out below to be those where critical accounting judgements have been applied and the resulting estimates and assumptions may lead to adjustments to the future carrying amounts of assets and liabilities.

**Useful Lives of Property, Plant and Equipment**

The Centre determines the estimated useful lives and related depreciation charges for its property, plant and equipment. This estimate is based on projected usage of the items of property, plant and equipment. It could change significantly as a result of technical innovations and competitor actions in response to severe industry cycles. The Centre's Officials will increase the depreciation charge where useful lives are less than provided estimated lives or it will write off or write down technically obsolete or non-strategic assets that have been abandoned or sold.

**2.4 Income Recognition**

The Centre recognizes income when the amount of income can be reliably measured, it is probable that future economic benefits will flow to the Centre and when specific criteria have been met for each of the Centre's activities as described below.



**AFRICAN CENTRE OF EXCELLENCE FOR GENOMICS OF INFECTIOUS DISEASES (ACEGID)**  
**Special Purpose Report and Financial Statements for the Year Ended 31 December, 2021**

**Significant Accounting Policies – (Cont'd)**

**2.4.1 Grants**

All grants received are recognized in the Special Purpose Report and Financial Statements as income over the period necessary to match their related research and academic expenditures or costs in line with IAS 20.

Grants are recognized as incomes only when the conditions have been substantially met as stipulated in the “terms of Reference” in each of the research projects.

**Unrestricted Grant Income**

Unrestricted grants (including Government grants - if any) are those received from unconditional transfers of cash or other assets to the Centre. Unrestricted grants in currencies other than Naira are recorded at exchange rates in effect at the time of receipt or, if outstanding as of 31 December, 2021 at the exchange rate in effect at the year end.

**Restricted Grant Income**

Restricted grants are those received from a transfer of resources to the Centre in return for past or future compliance to the operating activities of the Centre. Restricted grants in currencies other than Naira, with specific request to be paid in that currency as sponsor funds, are recorded as income and expenses at the exchange rate in effect at the time of payment.

Sponsors of research projects continue to be the main source of income for the Centre for the financial year under review.

**2.4.2 Interest Income**

Interest income includes income from financial assets at fair value through profit or loss, and income from cash and cash equivalents. They are recognized in the statement of income and expenditures using the effective interest rate method. The effective interest rate is the rate that exactly discounts the estimated future cash payments and receipts through the expected life of the financial instrument (or, when appropriate, a shorter period) to the carrying amount of the financial instrument on initial recognition.

**2.4.3 Other Income**

Other income is recognized at the fair value of the consideration received or receivable with respect to the tuition fees and other income from Master's degree and PhD students of the Centre. The Centre is not expected to engage in commercialization of their research products to third parties.

The Host University is responsible for the collection of tuition fees on behalf of the Centre from their Master and PhD students who enroll for the Centre's programmes. Students are charged fees for teaching instruction and facilities provided by the Centre to aid knowledge transfer process.

**Significant Accounting Policies – (Cont'd)**

**2.5 Taxation Expenses**

The Centre is a non-profit making organisation, hence it's not liable to Companies Income Tax under Companies Income Tax Act 2004. However, other transaction taxes such as Withholding Taxes, Value Added Taxes, are expensed in the Statement of Income and Expenditure Account during the year under review.

**2.6 Administrative Expenses**

The administrative expenses relate to costs of goods and services consumed by the Centre in carrying out its research, training and other administrative activities during the year.

The Centre's Officials reported such expenses in the year in which they are related and benefits derived. The expenses are reported in the "Statement of Income and Expenditure" for running of the Centre.

The classification of some of the major expenses' heads for reporting purposes during the year under review are as stated below:

- Seminars and Courses;
- Salaries and Wages;
- Printing and Stationery Expenses
- Flight and Airport Related Expenses;
- Repairs and Maintenances;
- Laboratory Consumables;
- Subscription Expenses (Local and International)
- Accreditation Cost;
- Subaward Projects; and
- Facilities and Administration.

They are reported at their actual costs and invoice prices to the Centre on each of the research activities.

**2.7 Property, Plant and Equipment**

**2.7.1 Recognition and Measurement**

The Centre recognizes items of property, plant and equipment at the time the cost is incurred. These costs include costs incurred initially to acquire or construct an item of property, plant and equipment as well as the costs of its dismantlement, removal or restoration, the obligation for which the Centre incurs as a consequence of using the item over its useful life.

Items of property, plant and equipment are measured at cost less accumulated depreciation and impairment losses. When parts of an item of property or equipment have different useful lives, they are accounted for as separate items (major components) of property, plant and equipment.



### **Significant Accounting Policies – (Cont'd)**

Depreciation methods, useful lives and residual values of property, plant and equipment are reviewed at each reporting date, if appropriate. Assets are impaired whenever events or changes in circumstances indicate that the carrying amount is less than the recoverable amount.

#### **2.7.2 Subsequent Costs**

The cost of replacing part of an item of property, plant and equipment is recognized in the carrying amount of the item if it is probable that the future economic benefits embodied within the part will flow to the Centre and its cost can be measured reliably. The carrying amount of the replaced part is derecognized. The costs of the day-to-day servicing of property, plant and equipment are recognized in the statement of income and expenditure as incurred.

#### **2.7.3 Depreciation of Property, Plant and Equipment**

Depreciation is recognized in the income statement on a straight-line basis to write down the cost of each asset, less their residual values over the estimated useful lives of each part of an item of property, plant and equipment.

Depreciation begins when an asset is available for use and ceases at the earlier of the date that the asset is derecognized or classified as held for sale in accordance with IFRS 5. A non-current asset or disposal group is not depreciated while it is classified as held for sale.

The estimated useful lives for the current and comparative periods are as follows:

Land	-	Nil
Building	-	2%
Buildings Improvement	-	10 %
IT Equipment	-	12.5 %
Furniture and Fittings	-	12.5 %
Office Equipment	-	12.5 %
Laboratory Equipment	-	12.5 %
Guest House Equipment	-	12.5 %
Plant and Machinery	-	15 %
Books	-	5%

#### **2.7.4 De-recognition**

An item of property, plant and equipment is derecognized upon disposal or when no future economic benefits are expected to arise from the continued use of the asset. Any gain or loss arising on the disposal or retirement of an item of property, plant and equipment is determined as the difference between the net disposal proceeds and the carrying amount of the assets and is recognized in the statement of income and expenditure under "other gains and losses."

**Significant Accounting Policies – (Cont'd)**

**2.7.5 Building Improvement**

All costs incurred on building structure are classified as “Building Improvement” within property, plant and equipment. These costs are recognized based on materiality and the expectation that they will enhance the useful life of the building.

The Centre does not have title to the land where the building structure is situated as its administrative office, hence all accumulated costs incurred on building Improvement are depreciated using the applicable rate in line with the Centre's depreciation policy.

**2.8 Intangible Assets**

An intangible asset is recognised when:

- it is probable that the expected future economic benefits that are attributable to the asset will flow to the entity; and
- the cost of the asset can be measured reliably.

Intangible assets are initially recognised at cost.

**Intangible Assets Acquired Separately**

Intangible assets with finite useful lives that are acquired separately are carried at cost less accumulated amortisation and accumulated impairment losses. Amortisation is recognised on a straight-line basis over their estimated useful lives. The estimated useful life and amortisation method are reviewed at the end of each reporting period, with the effect of any changes in estimate being accounted for on a prospective basis. Intangible assets with indefinite useful lives that are acquired separately are carried at cost less accumulated impairment losses.

Amortisation is recognised so as to write-off the cost of finite intangible assets, over their useful lives, using the straight-line method, on the following bases:

**Item Useful Life**

Computer software	3 – 5 years
-------------------	-------------



**Significant Accounting Policies – (Cont'd)**

**Derecognition of Intangible Assets**

An intangible asset is derecognised on disposal, or when no future economic benefits are expected from use or disposal. Gains or losses arising from derecognition of an intangible asset, measured as the difference between the net disposal proceeds and the carrying amount of the asset, are recognised in profit or loss when the asset is derecognised.

**2.9 Statement of Cash flows**

The Statement of Cash Flows is prepared using the indirect method. Changes in statement of financial position items that have not resulted in cash flows such as translation differences, fairvalue changes and other non-cash items, have been eliminated for the purpose of preparing the statement.

**2.10 Provision and Contingencies**

**2.10.1 Provisions**

Provisions are recognized when the Centre has a present legal or constructive obligation as a result of past events, that is when it is more likely than not that an outflow of resources will be required to settle the obligation and the amount can be reliably estimated or ascertained as at the reporting date – 31 December, 2021.

**2.10.2. Contingent Liabilities**

A contingent liability is a possible obligation that arises from past events and whose existence will be confirmed only by the occurrence or non-occurrence of one or more uncertain future events not wholly under the control of the Centre or a present obligation that arises from past event but is not recognized because it is not possible that an outflow of resources embodying economic benefits will be required to settle the obligation or the amount of the obligation cannot be measured with sufficient reliability.

However, contingent liabilities are only disclosed by way of note and not recognized as liabilities in the Statement of Financial Position.

**2.10.3. Contingent Assets**

Contingent assets are possible assets that arise from past events whose existence will be confirmed only by the occurrence or non-occurrence of one or more uncertain future events not wholly within the control of the entity. Contingent assets are only disclosed when an inflow of economic benefit is probable. Asset is recognized when the realization of income is virtually certain, in which case the related asset is no more contingent.

**Significant Accounting Policies – (Cont'd)**

**2.11 Financial Instruments**

The Centre has elected to adopt the International Financial Reporting Standard 9 (IFRS 9) in respect of the recognition, measurement and disclosure of financial instruments.

**2.11.1 Financial Assets**

Basic financial assets include trade and other receivables, cash and cash equivalents. These assets are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Such assets are subsequently carried at amortised cost using the effective interest rate method.

Financial assets are assessed for indicators of impairment at each statement of financial position date. If there is objective evidence of impairment, an impairment loss is recognised in the statement of income and expenditure. For financial assets carried at amortised cost the impairment loss is the difference between the carrying amount of the asset and the present value of the estimated future cash flows, discounted at the asset's original effective interest rate.

Financial assets are de-recognised when the contractual rights to the cash flows from the asset expire or are settled or substantially all of the risks and rewards of ownership of the asset are transferred to another party.

**(i) Recognition and Measurement**

Purchases and sales of financial assets are recognized on the trade date, which is the date on which the Centre commits to purchase or sell the asset. Financial assets are initially recognized at fair value plus transaction costs for all financial assets not carried at fair value through profit or loss.

Financial assets are derecognized when the rights to receive cash flows from the investments have expired or have been transferred and the Centre has transferred substantially all risks and rewards of ownership.

Hold-to-collect financial assets and financial assets at fair value through profit or loss are subsequently carried at fair value. Receivables and hold-to-collect investments are carried at amortized cost using the effective interest rate method.

**(ii) Classification**

The Centre classifies its financial assets in the following categories: financial assets at amortized cost. Management determines the classification of its financial assets at initial recognition. The Centre does not have any financial assets classified as fair value through profit or loss and hold-to-collect as at the reporting date.



**Significant Accounting Policies – (Cont'd)**

**2.11.1.1 Receivables**

The Centre initially recognises receivables on the date that they are originated. All other financial assets are recognised initially on the trade date at which the Centre becomes a party to the contractual provisions of the instrument. The Centre derecognises a financial asset when the contractual rights to the cash flows from the asset expire, or it transfers the rights to receive the contractual cash flows on the financial assets in a transaction in which substantially all the risks and rewards of ownership of the financial assets are transferred.

**2.11.1.2 Receivables and Other Receivables**

Receivables and other receivables, which generally have 30 days terms are recognized and carried at original amount less provision for impairment (if any). They are classified as current assets. Non-current receivables are recognized at fair value. Collectability of receivables is reviewed on an ongoing basis. An estimate for doubtful debts is made when collection of the full amount is no longer probable. Receivables which are known to be uncollectable are written off to the statement of income and expenditure.

**2.11.1.3 Cash and Cash Equivalents**

Cash and cash equivalents include cash at hand and deposit held at banks on local and domiciliary accounts.

**2.11.1.4 Impairment of Financial Assets**

The Centre assesses at the end of each reporting year whether there is objective evidence that a financial asset is impaired. A financial asset is impaired and impairment losses are incurred only if there is objective evidence of impairment as a result of one or more events that occurred after the initial recognition of the asset (a 'loss event') and that the loss event (or events) has an impact on the estimated future cash flows of the financial asset that can be reliably estimated.

Recognition of impairment provision under IFRS 9 is based on the expected credit loss (ECL) model. The ECL model is applicable to financial assets classified at amortised cost under IFRS 9: Financial instruments. The measurement of ECL reflects an unbiased and probability-weighted amount that is determined by evaluating a range of possible outcomes, time value of money and reasonable and supportable information that is available without undue cost or effort at the reporting date, about past events, current conditions and forecasts of future economic conditions.

The general approach assesses impairment based on changes in credit risk since initial recognition using the past due criterion. Financial assets classified as stage 1 have their ECL measured as a proportion of their lifetime ECL that results from possible default events that can occur within one year, while assets in stage 2 or 3 have their ECL measured on a lifetime basis. Non-trade receivables from related parties have been assessed for impairment under this approach.



**Significant Accounting Policies – (Cont'd)**

The simplified approach is applied for trade receivables from related parties and third-party customers. The simplified approach requires expected lifetime losses to be recognized from initial recognition of the receivables. This involves determining the expected loss rates using a provision matrix that is based on the Centre's historical default rates observed over the expected life of the receivable and adjusted forward-looking estimates. This is then applied to the gross carrying amount of the receivable to arrive at the loss allowance for the year.

Loss allowances for financial assets measured at amortized cost are deducted from the gross carrying amount of the related financial assets and the amount of the loss is recognized in profit or loss.

The carrying amount of the asset is reduced and the amount of the loss is recognized in the income statement. If a receivable or loan has a variable interest rate, the discount rate for measuring any impairment loss is the current effective interest rate determined under the contract. If, in a subsequent year, the amount of the impairment loss decreases and the decrease can be related objectively to an event occurring after the impairment was recognized (such as an improvement in the receivable's credit rating), the reversal of the previously recognized impairment loss is recognized in the income statement.

**2.11.2 Financial Liabilities.**

Basic financial liabilities include other payables. These liabilities are initially recognized at transaction price unless the arrangement constitutes a financing transaction. Other payables are obligations to pay for goods and services that have been acquired in the ordinary course of business from third parties or suppliers. Payables are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Payables are recognized initially at transaction price and subsequently measured at amortized cost using the effective interest rate method.

The Centre's holding in financial liabilities is at amortized cost. Financial liabilities are derecognized when extinguished.

**2.11.2.1 Liabilities Measured at Amortized Cost**

Financial liabilities that are not classified at fair value through profit or loss fall into this category and are measured at amortized cost. Financial liabilities measured at amortized cost are other payables.

**2.11.2.2 Other Payables**

Other payables are obligations to pay for goods and/or services that have been acquired in the ordinary course of dealing with third party to the Centre prior to the end of the reporting period. These amounts are usually settled on in line with the contractual agreement (if any) or as specified by the third party.



**AFRICAN CENTRE OF EXCELLENCE FOR GENOMICS OF INFECTIOUS DISEASES (ACEGID)**  
**Special Purpose Report and Financial Statements for the Year Ended 31 December, 2021**

**Significant Accounting Policies – (Cont'd)**

Accounts payable are classified as current liabilities if payment is due within one year or less (or in the normal operating cycle of the business if longer). If not, they are presented as non-current liabilities. Payables are recognized initially at fair value and subsequently measured at amortized cost using the effective interest rate method.

Financial liabilities are de-recognized when the liability is discharged, cancelled, or expires.

**2.11.3 Offsetting Financial Instruments**

Financial assets and liabilities are offset and the net amount reported in the statement of financial position, when there is a legally enforceable right to offset the recognized amounts and there is an intention to settle on a net basis or realize the asset and settle the liability simultaneously.

**2.12 Employee Benefits**

**2.12.1 Defined Contribution Plans**

The Centre operates a defined contribution based retirement benefit scheme for its staff, in accordance with the Pension Reform Act as amended in 2014 with employees contributing a minimum 8% and employer contributing 10% each of the employee's relevant emoluments. Payments to defined contribution retirement benefit plans are recognized as an expense when employees have rendered the service entitling them to the contributions.

**2.12.2 Short-term Employee Benefits**

Short-term employee benefits are expensed as the related service is provided. A liability is recognized for the amount expected to be paid as cash bonus if the Centre has a present legal or constructive obligation to pay this amount as salary as a result of past service provided by the employee and the obligation can be estimated reliably as at the financial year ended.

**3 NEW STANDARDS AND INTERPRETATIONS**

**3.1 Standards and Interpretations effective and adopted in current year**

For the preparation of these Special Purpose Report and Financial Statements, the following new, revised or amended pronouncements are mandatory for the first time for the financial year beginning on or after 1 January, 2021.



**Significant Accounting Policies – (Cont'd)**

**Amendment to IAS 1, 'Presentation of Financial Statements' and IAS 8, 'Accounting policies, Changes in accounting estimates and errors'**

The amendments clarify the definition of material and make IFRSs more consistent, but are not expected to have a significant impact on the preparation of Financial Statements. Information is material if omitting, misstating or obscuring it could reasonably be expected to influence decisions that the primary users of general-purpose Financial Statements make on the basis of those Special Purpose Report and Financial Statements, which provide financial information about a specific reporting entity.

The amendment clarifies that the reference to obscuring information addresses situations in which the effect is similar to omitting or misstating that information. It also states that an entity assesses materiality in the context of which the Special Purpose Report and Financial Statements as a whole requires an entity to:

- (i) use updated assumptions to determine current service cost and net interest for the remainder of the period after a planned amendment, curtailment or settlement, and
- (ii) recognize in profit or loss as past service cost, or a gain or loss on settlement, any reduction in a surplus, even if that surplus was not previously recognized because of the impact of the asset ceiling.

IAS 19 requires an entity to determine the amount of any past service cost, or gain or loss on settlement, by re-measuring the net defined benefit liability before and after the amendment, using current assumptions and the fair value of plan assets at the time of the amendment.

These requirements apply to all income tax consequences of dividends. Previously, it was unclear whether the income tax consequences of dividends should be recognized in profit or loss, or in equity, and the scope of the existing guidance was ambiguous. Annual periods beginning on or after 1 January, 2021.

Amendment to IAS 23 'Borrowing costs' (Annual Improvements to IFRSs 2015–2017 Cycle, issued in March 2018) - The amendments clarify that if a specific borrowing remains outstanding after the related qualifying asset is ready for its intended use or sale, it becomes part of general borrowings. Prospectively for borrowing costs incurred on or after the beginning of annual periods beginning on or after 1 January 2021.

**New and Amended Standards in issue but not yet effective**

The Centre has not applied the following new or amended standards that have been issued by the IASB but are not yet effective for the financial year beginning 1 January 2021 (the list does not include information about new or amended requirements that affect interim financial reporting or first-time adopters of IFRS since they are not relevant to IFRS Statements). The Directors anticipate that the new standards and amendments will be adopted in the Centre's Special Purpose Report and Financial Statements when they become effective. The Centre has assessed, where practicable, the potential effect of all these new standards and amendments that will be effective in future periods. Where IFRS and IFRIC interpretations listed below permits, the Centre has elected not to apply early adoption in the preparation of these Special Purpose Report and Financial Statements.



## **Significant Accounting Policies – (Cont'd)**

### **Amendments to References to the Conceptual Framework in IFRS Standards**

Together with the revised Conceptual Framework, which became effective upon publication on 29 March 2018, the IASB has also issued Amendments to References to the Conceptual Framework in IFRS Standards. The document contains amendments to IFRS 2, IFRS 3, IFRS 6, IFRS 14, IAS 1, IAS 8, IAS 34, IAS 37, IAS 38, IFRIC 12, IFRIC 19, IFRIC 20, IFRIC 22, and SIC-32."

Not all amendments, however, update those pronouncements with regard to references to and quotes from the framework so that they refer to the revised Conceptual Framework. Some pronouncements are only updated to indicate which version of the Framework they are referencing to (the IASC Framework adopted by the IASB in 2001, the IASB Framework of 2010, or the new revised Framework of 2018) or to indicate that definitions in the Standard have not been updated with the new definitions developed in the revised Conceptual Framework. The amendments, where they actually are updates, are effective for annual periods beginning on or after 1 January 2021, with early application permitted. The Management do not anticipate this to have material impact on the Special Purpose Report and Financial Statements.

### **4.0 Determination of Fair Values**

A number of the Centre's accounting policies and disclosure require the determination of fair value, both for financial and non-financial assets and liabilities. Fair values have been determined for measurement and/or disclosure purposes based on the following methods. When applicable, further information about the assumptions made in determining fair values is disclosed in the notes specific to that or liability.

#### **4.1 Receivables and Other Cash Flows Contractual Items**

The fair value of other receivables and items with cash flows contractual element is estimated as the present value of the future cash flows, discounted at market rates of interest at the reporting date. For other receivables with a remaining life of less than one year, the notional amount is deemed to reflect the fair value. Fair value which is determined for disclosure purposes is calculated on the present value of future principal and interest cash flows, discounted at market rates of interest at the reporting date.

#### **4.2 Payables and Other Current Liabilities**

Payables and other current liabilities with a remaining life of less than one year, the notional amount is deemed to reflect the face value as at the Centre financial year end.

### **5.0. Financial Risk Management**

Financial instrument in the statement of financial position comprises cash and cash equivalents (**note 8**), receivables (**notes 9**) and other payables (**note 13**).



**AFRICAN CENTRE OF EXCELLENCE FOR GENOMICS OF INFECTIOUS DISEASES (ACEGID)**  
**Special Purpose Report and Financial Statements for the Year Ended 31 December, 2021**

**Significant Accounting Policies – (Cont'd)**

**5.1 Financial Risk Factors**

The Centre's activities expose it to a variety of financial risks: market risk (including foreign exchange risk and interest rate risk). The Centre's overall risk management program focuses on the unpredictability of financial markets and seeks to minimize potential adverse effect on its financial and operational performance. Risk management is carried out by the Project Officials.

The Centre's foreign exchange and interest rate risks are continuously monitored by the Host University. The Audit and Risk Compliance Committee of Redeemer's University approves written principles for overall risk management, as well as written policies covering specific areas, such as foreign exchange risk, and interest-rate risk.

**5.1.1 Market Risk**

Market risk is the potential for adverse changes in the value of a trading or an investment portfolio due to changes in market risk variables such as interest rates, and foreign exchange rates.

**5.1.1.1 Foreign Exchange Risk**

Foreign exchange risk arises when future commercial transactions and recorded assets and liabilities are denominated in a currency that is not the Centre's functional currency e.g. foreign denominated grants, purchases and sales transactions. The Centre manages its foreign exchange risk by revising cost estimates of orders based on exchange rate fluctuations. The table below shows the impact on ACEGID's reserves if the exchange rate between the following currency on the Nigerian Naira had increased or decreased by 10%, with all other variables held constant.

ACEGID Increase or decrease in rate Impact on income and expenditure:	2021	2021	2020	2020
	Increase	Decrease	Increase	Decrease
US Dollar 10% (2020:10%)	431,463,125	(431,463,125)	196,551,732	(196,551,732)
Pound 10%	5,819,646	(5,819,646)	13,120,529	(13,120,529)
	<b>437,282,771</b>	<b>(437,282,771)</b>	<b>209,672,261</b>	<b>(209,672,261)</b>
<b>Impact on equity:</b>				
US Dollar 10% (2020:10%)	431,463,125	(431,463,125)	196,551,732	(196,551,732)
Pound 10%	5,819,646	(5,819,646)	13,120,529	(13,120,529)
	<b>437,282,771</b>	<b>(437,282,771)</b>	<b>209,672,261</b>	<b>(209,672,261)</b>



**Significant Accounting Policies – (Cont'd)**

**5.1.1.2 Interest Rate Risk**

The Centre holds short term, highly liquid bank deposits at fixed and variable interest rates. No limits are placed on the ratio of variable rate borrowing to fixed rate borrowing if the Centre needs such facilities. The Centre does not have or hold any investments in quoted corporate bonds that are of a fixed rate and carried at fair value through profit or loss. Therefore, the Centre is not exposed to fair value interest rate risk as at the reporting date.

**5.1.1.3 Other Price Risk**

There are no financial instruments exposed to other price risk from the Centre transactions.

**5.1.1.4 Credit Risk**

Credit risk arises from cash and cash equivalents and deposits with banks as well as other receivables. The Centre has no significant concentrations of credit risk. It has policies in place to guide against unnecessary credit risk. Receivables attributable to different projects are short term fund transfers for on-going research-based activities awaiting grant from the donors. Therefore, receivables redeemed within a short-term (30 days) are not considered to be impaired, and are carried at their reported recoverable value.

**Credit Quality of Financial Assets**

The credit quality of financial assets that are neither past due nor impaired can be assessed by reference to external credit ratings (if available) or to historical information about counterparty default rates.

**5.1.1.5 Liquidity Risk**

Prudent liquidity risk management implies maintaining sufficient cash and bank deposit with the banks, the availability of funding through an adequate amount committed from the various donors to the Centre for different research related activities conducted during the period under review. Due to the dynamic nature of the Centre expenditures profile, the Project Accountant maintains flexibility in funding by being committed to on-going research related and training activities from time to time. Management monitors rolling forecasts of the Centre's liquidity reserve comprising cash and cash equivalents on the basis of expected cash flow. Surplus cash held by the Centre over and above balance required for working capital management are invested in interest bearing current accounts and short-term deposits, choosing instruments with appropriate maturities or sufficient liquidity to provide sufficient headroom. At the reporting date the Centre held cash and cash equivalents of ₦4.9 billion **(As at 5 months ended 31 December 2020: ₦2.6 billion).**

**5.1.1.6 Operational Risk**

Operational risk is the risk relating to direct or indirect losses arising from a wide variety of items associated with Centre's processes, personnel, technology and infrastructure from external factors outside liquidity risks arising from legal and regulatory requirements and generally accepted standards of the corporate behavior.

AFRICAN CENTRE OF EXCELLENCE FOR GENOMICS OF INFECTIOUS DISEASES (ACEGID)  
Special Purpose Report and Financial Statements for the Year Ended 31 December, 2021

Notes to the Financial Statements

6 PROPERTY, PLANT AND EQUIPMENT

31/12/2021  
(12 Months)

	BUILDING IMPROVEMENTS	LABORATORY EQUIPMENT	PLANT AND MACHINERY	MOTOR VEHICLE	FURNITURE & FITTINGS	IT EQUIPMENT	OFFICE EQUIPMENT	CAPITAL W.I.P	TOTAL
	=N=	=N=	=N=	=N=	=N=	=N=	=N=	=N=	=N=
<b>COST</b>									
As at 1 January, 2021	17,656,621	1,155,739,587	30,777,811	129,986,792	149,967,241	55,716,233	25,686,008	1,202,633,905	2,768,164,198
Disposal	-	-	-	(25,530,000)	-	-	-	-	(25,530,000)
Additions	-	703,298,970	31,917,000	87,027,116	2,059,275	28,159,926	18,916,999	237,506,119	1,108,885,405
<b>As at 31 December , 2021</b>	<b>17,656,621</b>	<b>1,859,038,557</b>	<b>62,694,811</b>	<b>191,483,908</b>	<b>152,026,516</b>	<b>83,876,159</b>	<b>44,603,007</b>	<b>1,440,140,024</b>	<b>3,851,519,603</b>
<b>DEPRECIATION</b>									
As at 1 January, 2021	8,837,441	234,308,676	10,303,581	16,977,108	16,229,048	9,689,456	10,740,364	-	307,085,674
Disposal	-	-	-	(10,212,000)	-	-	-	-	(10,212,000)
Charge for the year	1,765,662	182,854,210	7,280,015	33,738,388	18,841,171	8,446,421	5,002,503	-	257,928,370
<b>As at 31 December , 2021</b>	<b>10,603,103</b>	<b>417,162,886</b>	<b>17,583,596</b>	<b>40,503,496</b>	<b>35,070,219</b>	<b>18,135,877</b>	<b>15,742,867</b>	<b>-</b>	<b>554,802,044</b>
<b>NET BOOK VALUE</b>									
<b>As at 31 December , 2021</b>	<b>7,053,518</b>	<b>1,441,875,671</b>	<b>45,111,215</b>	<b>150,980,412</b>	<b>116,956,297</b>	<b>65,740,282</b>	<b>28,860,140</b>	<b>1,440,140,024</b>	<b>3,296,717,558</b>
As at 31 December, 2020	8,819,180	921,430,911	20,474,230	113,009,684	133,738,193	46,026,777	14,945,644	1,202,633,905	2,461,078,524

Capital work-in-progress represents the accumulated costs incurred on the Centre's New Ultra Modern Research Laboratory Building under construction within the host university site. The total sum of **N1.4b** had been incurred by the Project Officials as at 31 December, 2021.



AFRICAN CENTRE OF EXCELLENCE FOR GENOMICS OF INFECTIOUS DISEASES (ACEGID)  
Special Purpose Report and Financial Statements for the Year Ended 31 December, 2021

Notes to the Financial Statements

6 PROPERTY, PLANT AND EQUIPMENT

31/12/2020  
(5 Months)

	BUILDING IMPROVEMENTS =N=	LABORATORY EQUIPMENT =N=	PLANT AND MACHINERY =N=	MOTOR VEHICLE =N=	FURNITURE & FITTINGS =N=	IT EQUIPMENT =N=	OFFICE EQUIPMENT =N=	CAPITAL W.I.P =N=	TOTAL =N=
<b>COST</b>									
As at 1 August, 2020	17,656,621	890,039,645	21,987,364	65,669,319	149,967,241	27,099,836	25,686,008	1,072,099,601	2,270,205,635
Additions	-	265,699,942	8,790,447	64,317,473	-	28,616,397	-	130,534,304	497,958,563
<b>As at 31 December , 2020</b>	<b>17,656,621</b>	<b>1,155,739,587</b>	<b>30,777,811</b>	<b>129,986,792</b>	<b>149,967,241</b>	<b>55,716,233</b>	<b>25,686,008</b>	<b>1,202,633,905</b>	<b>2,768,164,198</b>
<b>DEPRECIATION</b>									
As at 1 August, 2020	8,101,748	173,196,178	8,875,183	11,212,998	8,418,254	7,456,796	9,402,551	-	226,663,708
Additions	735,693	61,112,498	1,428,398	5,764,110	7,810,794	2,232,660	1,337,813	-	80,421,966
<b>As at 31 December , 2020</b>	<b>8,837,441</b>	<b>234,308,676</b>	<b>10,303,581</b>	<b>16,977,108</b>	<b>16,229,048</b>	<b>9,689,456</b>	<b>10,740,364</b>	<b>-</b>	<b>307,085,674</b>
<b>NET BOOK VALUE</b>									
<b>As at 31 December , 2020</b>	<b>8,819,180</b>	<b>921,430,911</b>	<b>20,474,230</b>	<b>113,009,684</b>	<b>133,738,193</b>	<b>46,026,777</b>	<b>14,945,644</b>	<b>1,202,633,905</b>	<b>2,461,078,524</b>
As at 1 August, 2020	9,554,873	716,843,467	13,112,181	54,456,321	141,548,987	19,643,040	16,283,457	1,072,099,601	2,043,541,926

Capital work-in-progress represents the accumulated costs incurred on the Centre's New Ultra Modern Research Laboratory Building under construction within the host university site. The total sum of **N1.2b** had been incurred by the Project Officials as at 31 December, 2020.

AFRICAN CENTRE OF EXCELLENCE FOR GENOMICS OF INFECTIOUS DISEASES (ACEGID)  
Special Purpose Report and Financial Statements for the Year Ended 31 December, 2021

Notes to the Financial Statements - (Cont'd)

	31/12/2021 (12 months) 2021 =N=	31/12/2020 (5 months) 2020 =N=
<b>7 INTANGIBLE ASSET</b>		
<b>Cost:</b>		
As at 1 January,	12,929,446	8,929,447
Additions during the year	-	3,999,999
As at 31 December,	<u>12,929,446</u>	<u>12,929,446</u>
<b>Amortisation</b>		
As at 1 January,	1,422,725	-
Charge for the year	4,309,384	1,422,725
As at 31 December,	<u>5,732,109</u>	<u>1,422,725</u>
<b>Carrying Amount</b>		
As at 31 December,	<u>7,197,337</u>	<u>11,506,721</u>
<b>8 CASH AND CASH EQUIVALENTS</b>		
Access Bank Current Account-NGN (World Bank)	77,317,438	61,472,364
Access Bank Current Account-Dom (World Bank)	62,757,316	50,421,323
	<u>140,074,754</u>	<u>111,893,687</u>
Access Bank H3 Africa Current Account-NGN	50,747,140	18,518,472
Access Bank H3 Africa Account-Dom	259,629,067	213,733,842
	<u>310,376,207</u>	<u>232,252,314</u>
Access Bank WB-ACEGID IMPACT Current Account - NGN	2,748,053	27,471,338
Access Bank WB-ACEGID IMPACT Current Account - Dom	408,728	379,500
Access Bank FAST GRANTS Current Account - NGN	942	942
Access Bank FAST GRANTS Domiciliary Account	20,491,081	64,457,612
	<u>23,648,804</u>	<u>92,309,392</u>
Access Bank JWARG Current Account	8,412,290	52,108,043
Access Bank JWARG Account-Dom	130,164,053	148,121,241
	<u>138,576,343</u>	<u>200,229,284</u>
Access Bank WB-BBSRC Domiciliary Account	15,618,470	6,673,880
Access Bank WB-BBSRC Current Account	270,611	270,611
	<u>15,889,081</u>	<u>6,944,491</u>
Access Bank WB-ACEGID Domiciliary Account (ESCR)	10,096,507	42,438,658
Access Bank WB-ACEGID Current Account (ESCR)	134,944	3,854,801
	<u>10,231,451</u>	<u>46,293,459</u>
Access Bank CEPI Domiciliary Account	65,808,366	78,946,983
Access Bank CEPI-BIOSTANDARD Current Account	1,981,404	20,323,687
Access Bank CEPI-EPIIMIOLOGY Domiciliary Account	1,711,625	1,572,826
Access Bank CEPI-EPIIMIOLOGY Current Account	404,825	404,329
	<u>69,906,220</u>	<u>101,247,825</u>
Access Bank WELLCOME Domiciliary Account	37,385,231	127,648,644
Access Bank WELLCOME Current Account	20,973,684	7,379,565
	<u>58,358,915</u>	<u>135,028,209</u>
Access Bank ROCKEFELLER-UG Domiciliary Account	10,457,927	-
Access Bank ROCKEFELLER-UG Current Account	13,128,826	-
	<u>23,586,753</u>	<u>-</u>
Access Bank PHA4GE GRANTS Domiciliary Account	965,426	-
Access Bank PHA4GE GRANTS Current Account	161,156	-
	<u>1,126,582</u>	<u>-</u>
Access Bank EID032 Domiciliary Account	354,203,116	-
Access Bank EID032 Current Account	17,864,560	-
	<u>372,067,676</u>	<u>-</u>
Access Bank AUDACIOUS-SENTINEL Domiciliary Account	3,119,433,939	1,321,020,920
Access Bank AUDACIOUS-SENTINEL Current Account	276,743,952	281,339,368
	<u>3,396,177,891</u>	<u>1,602,360,288</u>
Access Bank CAMBRIDGE Domiciliary Account	5,090,425	-
Access Bank Africa CDC/ASLM Domiciliary Account	32,972,081	-
Access Bank WARN-ID Domiciliary Account	57,342,034	-
Access Bank Africa CAMRA DSI Domiciliary Account	156,707,532	-
Access Bank BMGF Domiciliary Account	62,678,286	-
Access Bank AAS Domiciliary Account	43,802,884	-
Access Bank NIH Account-Domiciliary Account	42,332,549	41,838,532
	<u>400,925,791</u>	<u>41,838,532</u>
	<u>4,960,946,468</u>	<u>2,570,397,481</u>
The Centre opened a designated bank account for each of the project under sponsorship to ease reporting and tracking of grants received for such purpose. The Centre complied with the conditions of the grants, which specify that certain percentage of the project funds is spent on partnership activities as entailed in the partnership action plan and budget.		
<b>9 RECEIVABLES</b>		
Receivables from Redeemer's University - RUN	28,293,229	28,293,228
Receivables from other donors (Note 9.1)	763,281,395	700,182,488
	<u>791,574,624</u>	<u>729,073,716</u>
Receivables from Redeemers University includes tuition fees from the students being trained by the Centre to date. Payments were made directly to the University's bank account by the students.		
* Receivables from donors represent amount due to other projects from ACE-IMPACT and inter-project receivables.		



**AFRICAN CENTRE OF EXCELLENCE FOR GENOMICS OF INFECTIOUS DISEASES (ACEGID)**  
**Special Purpose Report and Financial Statements for the Year Ended 31 December, 2021**

**Notes to the Financial Statements - (Cont'd)**

	31/12/2021 (12 months) 2021 =N=	31/12/2020 (5 months) 2020 =N=
<b>9.1 RECEIVABLE FROM OTHER DONORS</b>		
JWARG	-	138,000
Audacious	16,748,500	92,648,500
H3Africa	516,033,988	511,033,988
CEPI	15,000,000	460,000
Wellcome Trust	96,500,000	96,500,000
Henry Jackson Foundation	117,347,224	-
CAMBRIDGE	460,000	-
CAMRA DSI	1,191,683	-
	<u>763,281,395</u>	<u>700,780,488</u>
<b>10 OTHER RECEIVABLES</b>		
Cash advance for property, plant and equipment acquisition	33,875,556	4,897,639
	<u>33,875,556</u>	<u>4,897,639</u>
Other receivables relate to payment for the acquisition of PPE yet to be delivered as at 31 December, 2021.		
<b>11 PREPAYMENT</b>	31/12/2021	31/12/2020
	=N=	=N=
Current - Rent and Motor Vehicle Insurance	1,200,000	1,200,000
Non-Current - Rent Prepayment	<u>2,871,123</u>	<u>3,100,000</u>
The prepayment relates to advance payment for accommodation of researcher in Abakaliki Centre and motor vehicle insurance cover on the Centre vehicles in use for operational activities. The amount stated is for the remaining period - rent (31 months).		
<b>12 RESERVES</b>	31/12/2021	31/12/2020
	=N=	=N=
As at 1 January	4,881,493,716	4,474,590,758
Surplus for the year	3,154,517,550	406,902,958
As at 31 December	<u>8,036,011,266</u>	<u>4,881,493,716</u>
<b>13 OTHER PAYABLES</b>		
Other Payables	293,812,949	198,095,621
Payable to donors (Note 13.1)	763,281,395	700,780,488
Withholding Tax Payable	229,768	244,471
Accrued Expenses	1,047,288	639,785
	<u>1,058,371,400</u>	<u>899,760,365</u>
<b>13.1 PAYABLES TO DONORS</b>		
Joint West Africa Research Group (JWARG)	-	460,000
CEPI	15,000,000	-
The Wellcome Trust Limited	96,500,000	96,500,000
Audacious-Sentinel	16,748,500	92,648,500
Henry Jackson Foundation	117,347,224	-
H3Africa	517,685,671	511,171,988
	<u>763,281,395</u>	<u>700,780,488</u>
* Payables to donors represent amounts incurred on projects being carried on behalf of ACEGID for the year under review.		
<b>14 RESEARCH GRANTS</b>	31/12/2021	31/12/2020
	=N=	=N=
Grant from World Bank	40,327,000	-
Grant from Joint West Africa Research Group (JWARG)	-	119,276,471
Grant from Human Heredity and Health in Africa (H3)	369,207,000	152,528,390
Grant from Audacious-Sentinel	2,213,889,662	683,086,718
Grant from CEPI- BIOSTANDARD	7,164,079	21,585,201
Grant from FAST GRANTS	-	94,867,410
Grant from Wellcome Trust Limited	12,070,241	20,837,205
Grant from CAMBRIDGE	5,367,964	-
Grant from Africa CDC/ASLM	38,566,110	-
Grant from PHA4GE	12,291,000	-
Grant from WARN-ID	56,893,284	-
Grant from AAS	40,249,770	-
Grant from EID032 PROJECT	747,808,391	-
Grant from ROCKEFELLER-UG	43,226,105	-
Grant from CAMRA DSI	82,104,000	-
Grant from BMGF	144,442,564	-
	<u>3,813,607,170</u>	<u>1,092,181,395</u>

The Centre complied with the conditions as specified in the award letter by the Sponsors for the grants. This was based on the specific responsibility for ensuring that a certain percentage of the project funds is spent on partnership activities as agreed in the partnership action plan and budget.



**Notes to the Financial Statements - (Cont'd)**

**14.1 World Bank Project - Results based funding**

During the financial year under review, the Centre received the fund of **N40,327,000** from World Bank (**31 December, 2020: Nil**) for research and academic related activities on genomics of infectious diseases in Africa continent. The Centre is expected to meet the following conditions before accessing the fund.

- i To meet set goals and milestones as detailed out in the award letter;
- ii Submission of measurable outcomes, which are verified by independent verifiers appointed by the funders;
- iii Results achieved as reported by the verifier;
- iv Expenses incurred through the involvement of participating partners on the project and subaward expense; and
- v The indicators measured include research outcome, number of students trained, submission of account report, internship, and other operating expenses such as personnel costs, laboratory consumables and others.

**14.2 Human Heredity and Health in Africa - (H3 Africa)**

The donor released fund for specific research activities usually on quarterly basis, during the year ended 31 December, 2021, the Centre received the sum of **N369,207,000 (\$180,000:00)** The donor committed the sum of \$1,000,000 US dollar for research activities on genomics and environmental determinants of common disease in Africa based on the terms of reference. The Centre Officials must meet the specified terms and conditions before assessing the grant are:

- i Approved expenditure proposal based on the milestones or objectives set by the Centre;
- ii Cost of testing of blood sample for evidence of the infectious diseases are reported as actual expenses;
- iii Approved administrative expenses such as personnel cost, transport, training and other related expenditures;
- iv Acquisition of equipment for researcher and teaching purposes;
- v Other direct costs (ODC's) are to be listed and described separately;
- vi Carry out the work ethics diligently within the scope allowed by the funder donor; and
- vii Detailed description of works and services performed during the period under review for reporting.

**14.3 Joint West Africa Research Group (JWARG)**

During the year under review, the donor - JWARG did not release any fund for research and studying of infectious diseases such as malaria, yellow fever, lassa fever and dengue in the West Africa region. The Centre is expected to meet the following conditions before accessing the fund.

- i The Centre shall submit monthly invoices for services performed and milestones completed in the previous month for reimbursement;
- ii Acquisition of equipment and personnel costs directly incurred on the project;
- iii Cost of laboratory consumables materials used for sample testing in line with the research principles;
- iv Cost of free diagnostic of patients in areas of specialization;
- v Reimbursement of expenses for researchers and invigilators on the project;
- vi Any other direct costs are to be listed and described separately for verification purposes;
- vii Adhere to international safety and ethical guidelines on research related activities.

**14.4 The ELMA Relief Foundation (Audacious Sentinel)**

During the year under review, the sum of **N2.213 billion (\$9,599,930)** was received through the Centre banker from the donor as at 31 December, 2021 for research activities. The amount disbursed was based on the budget submitted and approved by the funder as a conditions for assessing the fund. The funding is to be used for research activities on pandemic and early detection of diseases/viruses for a duration of 6 years (2020 to 2025).

**14.5 FAST GRANTS**

During the year under review a new grant was established for Covid - 19 related science and research purpose, in which the sum of **N103,239,240.20 2020 (\$249,980:00)** was released by the donor as at 31 December, 2020. No grant was received as at **31 December, 2021**. The amount disbursed was based on the approved budget submitted by the Centre Management in line with the terms of reference for accessing the grant.

The grants must be used for work on Covid - 19 related science and all manuscripts reporting work are required to be forwarded to the donor on six months basis.



Notes to the Financial Statements - (Cont'd)

- 14.6 Advanced Funding - Coalition for Epidemic Preparedness Innovation - CEPI**  
This is release of funds by the donors/funders for specific period usually annually. The said amount is based on the budget submitted and approved by the funders. This model is used for funders such as NIH and CEPI. The funding is also to be used to procure items as stated in the budget approved in the RFA. The account statement at the end of the year is certified by the University Bursar and Vice Chancellor.  
The sum of **N7,164,078 (\$17,490:00)** was received from Coalition for Epidemic Preparedness Innovation - CEPI funder for the year ended 31 December, 2021.
- 14.7 The Wellcome Trust Limited**  
During the year under review, the sum of **N12,070,240.56 (£22,872:00)** was released by the donor as at 31 December, 2021. This is fund made available by the donor for research activities on genomics and environmental determinants of common diseases in Africa based on the budget submitted and approved by the donor. The Centre is expected to meet the following conditions before accessing the fund.
- i Approved proposal base on the milestones and/or objectives set by the Centre in respect of the project;
  - ii Cost of testing of blood samples used for the research activities are reported as per invoice prices;
  - iii Administrative expenses incurred such as personnel cost, transport, training and other related expenditures;
  - iv Acquisition of equipment for researcher and teaching purposes in line with the guidelines stated in the approval letter;
  - v Other direct costs (ODC's) incurred are to be listed and described separately;
  - vi Carry out the work ethics diligently within the scope allowed and in compliance with international benchmarks; and
  - vii Details description of works and services performed during the year under review.
- 14.8 Africa Society of Laboratory Medicine (ASLM)**  
During the year under review, the sum of **N38,566,110 (£101,500:00)** was released by the donor as at 31 December, 2021. This is fund made available by the donor for research activities on genomics and environmental determinants of common diseases in Africa based on the budget submitted and approved by the donor.
- 14.9 Public Health Alliance for Genomic Epidemiology**  
During the year under review, the sum of **N12,291,000 (\$30,000:00)** was released by the donor as at 31 December, 2021. This is fund made available by the donor for research activities on genomics and environmental determinants of common diseases in Africa based on the budget submitted and approved by the donor.
- 14.10 The African Academy of Sciences**  
During the year under review, the sum of **N40,249,770 (\$106,060:00)** was released by the donor as at 31 December, 2021. This is fund made available by the donor for Covid-19 research and development goals for Africa based on the budget submitted and approved by the donor.
- 14.11 The Henry M. Jackson Foundation**  
During the year under review, the sum of **N747,808,390.78 (\$208,494.26)** was released by the donor as at 31 December, 2021. This is fund made available by the donor for the incidence of Lassa virus infection in Southern Nigeria based on the budget submitted and approved by the donor.
- 14.12 The Rockefeller Foundation - UG**  
During the year under review, the sum of **N43,226,105.27 (\$105,499)** was released by the donor as at 31 December, 2021. This is fund made available by the donor for tracking Covid-19 infections in West Africa to guide public health interventions based on the budget submitted and approved by the donor.
- 14.13 CAMRA DSI**  
During the year under review, the sum of **N82,104,000 (\$400,000)** was released by the donor as at 31 December, 2021. This is fund made available by the donor for combating antimicrobial resistance in Africa using data science based on the budget submitted and approved by the donor.
- 14.14 WARN-ID - West African Research Network for Infectious Diseases (WARN-ID)**  
During the year under review, the sum of **N56,893,284.12 (\$138,845.85)** was released by the donor as at 31 December, 2021. This is fund made available by the donor for combating emerging infectious diseases based on the budget submitted and approved by the donor.

**AFRICAN CENTRE OF EXCELLENCE FOR GENOMICS OF INFECTIOUS DISEASES (ACEGID)**  
**Special Purpose Report and Financial Statements for the Year Ended 31 December, 2021**

**Notes to the Financial Statements - (Cont'd)**

**14.15 BMGF - Bill and Melinda Gates Foundation**

During the year under review, the sum of **N144,442,564.05 (\$151,763.50)** was released by the donor as at 31 December, 2021. This is fund made available by the donor for combating emerging infectious diseases based on the budget submitted and approved by the donor.

**14.16 University of Cambridge**

During the year under review, the sum of **N5,367,964.48 (\$9,476)** was released by the donor as at 31 December, 2021. This is fund made available by the donor for combating emerging infectious diseases based on the budget submitted and approved by the donor.

	<b>31/12/2021</b>	<b>31/12/2020</b>
	<b>=N=</b>	<b>=N=</b>
<b>15 INTEREST INCOME</b>		
Interest on Bank Accounts	<b>460,255</b>	<b>61,218</b>

**16 REGISTRATION AND TUITION FEES**

Registration Fees	-	-
*Tuition Fees	-	1,250,000
	<b>-</b>	<b>1,250,000</b>

Registration and tuition fees are fees received from the Masters and PhD Students enrolled at the Centre of Excellence. These fees are collected by the Host University - Redeemer's University on behalf of the Centre to be remitted at a later date. However, during the year ended 31 December, 2021, there was no tuition fees due to tuition waiver.

	<b>31/12/2021</b>	<b>31/12/2020</b>
	<b>=N=</b>	<b>=N=</b>
<b>17 EXCHANGE GAIN</b>		
*Exchange gain (Unrealized)	-	-
	<b>2,054,343,175</b>	<b>244,404,549</b>
	<b>2,054,343,175</b>	<b>244,404,549</b>

\* Unrealised exchange gains have arisen from the translation of foreign currency denominated bank balances at each reporting date.

	<b>31/12/2021</b>	<b>31/12/2020</b>
	<b>=N=</b>	<b>=N=</b>
<b>18 OTHER INCOME</b>		
Donations Received	<b>75,892,410</b>	-
Sequencing Fees	<b>10,769,531</b>	4,273,193
Gain on Disposal	<b>3,063,600</b>	-
Bench Fees	<b>300,000</b>	-
Other Research Income	<b>2,150,000</b>	-
IGR - COVID -19 Test	<b>87,893,898</b>	23,172,353
IGR - Facilities and Administrative Fees	<b>44,097,957</b>	56,735,250
	<b>224,167,396</b>	<b>84,180,796</b>



**AFRICAN CENTRE OF EXCELLENCE FOR GENOMICS OF INFECTIOUS DISEASES (ACEGID)**  
**Special Purpose Report and Financial Statements for the Year Ended 31 December, 2021**

**Notes to the Financial Statements - (Cont'd)**

List of donors included in other income	31/12/2021 =N=	31/12/2020 =N=
African Union- CDC Africa Control for Disease Control & Prevention	<b>75,892,410</b>	

**19 Information on Employees Emoluments**

The number of employees in receipt of emoluments, excluding allowances, within the following range were:

N	Up to N	31/12/2021 (12 months) Number	31/12/2020 (5 months) Number
100,001	500,000	1	1
500,001	1,000,000	1	1
1,000,001	2,000,000	2	2
2,000,001	3,000,000	1	1
		<b>5</b>	<b>5</b>

The Centre maintained 5 members of staff on full employment with conditions of engagement as detailed out in their letters of appointment.

In addition, the Centre makes use of contract staff to meet its employee requirements, which are renewable based on project demands.

The sum of N884m (5 months period ended 31 December 2020: N336m) were incurred as salaries and wages for

the reporting year by the Centre as employees remuneration to both regular and contract staff respectively.

The components of the Salaries and Wages for the year ended are as follows:

	31/12/2021 (12 months) =N=	31/12/2020 (5 months) =N=
<b>ACEGID</b>		
Contract Staff	6,690,000	1,711,900
<b>BBSRC</b>		
Investigators	-	8,961,880
<b>H3Africa</b>		
Investigators & Contract Staff	29,907,263	10,845,833
<b>CEPI EPI</b>		
Investigators	-	-
<b>WELLCOME</b>		
Contract Staff	55,196,575	14,126,835
<b>CPEI BIO STANDARD</b>		
Investigators	26,251,749	5,955,743
<b>AUDACIOUS</b>		
Investigators & Contract Staff	549,264,057	267,700,246
<b>NIH</b>		
Students	-	-
<b>FAST GRANTS</b>		
Contract Staff	47,687,100	22,770,000
<b>JWARG</b>		
Investigators	62,943,000	4,051,013
Contract Staff	-	-
<b>PHA4GE</b>		
Investigators	5,124,933	-
<b>ASLM</b>		
Investigators	4,107,200	-
<b>ROCKEFELLER-UG</b>		
Investigators	2,500,000	-
<b>CAMBRIDGE</b>		
Investigators	30,000	-
<b>HENRY JACKSON FOUNDATION</b>		
Investigators	94,303,260	-
	<b>884,005,136</b>	<b>336,123,450</b>

**AFRICAN CENTRE OF EXCELLENCE FOR GENOMICS OF INFECTIOUS DISEASES (ACEGID)**  
**Special Purpose Report and Financial Statements for the Year Ended 31 December, 2021**

**Notes to the Financial Statements - (Cont'd)**

**20 Classification of Financial Instrument - IFRS - 9**

The following table and the accompanying notes below explain the classification, measurement and disclosure under IFRS 9 for each class of the Centre's financial assets and financial liabilities as at 31 December 2021.

	Notes	IFRS 9 Classification	Carrying amount as at December 31, 2021	Impairment for the year	Balance as at December 31, 2021
<b>Financial Assets</b>			<b>=N=</b>	<b>=N=</b>	<b>=N=</b>
Receivables	8	Amortised cost	791,574,624	-	791,574,624
Other receivables	9	Amortised cost	33,875,556	-	33,875,556
Cash and cash equivalents	7	Amortised cost	4,960,946,468	-	4,960,946,468
<b>Total financial assets</b>			<b>5,786,396,648</b>	-	<b>5,786,396,648</b>
<b>Financial liabilities</b>					
Accrual		Amortized cost	1,047,288	-	1,047,288
<b>Total financial liabilities</b>			<b>1,047,288</b>	-	<b>1,047,288</b>

The corresponding amounts for the five- month period ended 31 December, 2020 are as stated below:

	Notes	IFRS 9 Classification	Carrying amount as at December 31, 2020	Impairment for the period	Balance as at December 31, 2020
<b>Financial Assets</b>			<b>=N=</b>	<b>=N=</b>	<b>=N=</b>
Receivables	8	Amortised cost	729,073,716	-	729,073,716
Other receivables	9	Amortised cost	5,252,264	-	5,252,264
Cash and cash equivalents	7	Amortised cost	2,570,397,481	-	2,570,397,481
<b>Total financial assets</b>			<b>3,304,723,461</b>	-	<b>3,304,723,461</b>
<b>Financial liabilities</b>					
Accruals		Amortised cost	639,785	-	639,785
<b>Total financial liabilities</b>			<b>639,785</b>	-	<b>639,785</b>

**21 Financial Commitment**

The financial commitment to the Centre is limited to the grant received from donors as indicated in these Special Purpose Report and Financial Statements for different research related activities. However, the Centre officials are of the opinion that, the Centre has sufficient financial resources towards the completion of the New Ultra Modern Laboratory Building which is in the final stage of completion as at year ended 31 December, 2021.

**22 Events after Reporting Date**

No events or transactions have occurred since the statement of financial position date, which would have a material impact on the Special Purpose Report and Financial Statements at that date or which need to be disclosed in these Special Purpose Report and Financial Statements in order not to make them misleading as to the financial position or result of operations at the statement of financial position date.

**23 Contingent Liability**

There were no contingent liabilities against the Centre in respect of the researcher and teaching activities as at 31 December, 2021 (**31 December, 2020: Nil**).

**24 Special Purpose Report and Financial Statements**

These Special Purpose Report and Financial Statements have been prepared exclusively for the grants provided by the World Bank for the prevention and eradication of Infectious diseases such as malaria, lassa fever etc. The grant was approved on April 1, 2015 for an initial period of five years ended on March 31, 2020. However, a new grant, tagged ACE IMPACT has been approved for another five years running from 1 August, 2020 to 31 July, 2025. Therefore, these Special Purpose Report and Financial Statements are not the annual report and financial statements of the Centre, but a Special Purpose Report and Financial Statements meant for monitoring the progress of the ACE IMPACT project as at year ended 31 December, 2021.



**AFRICAN CENTRE OF EXCELLENCE FOR GENOMICS OF INFECTIOUS DISEASES (ACEGID)**  
**Special Purpose Report and Financial Statements for the Year Ended 31 December, 2021**

**Notes to the Financial Statements - (Cont'd)**

**25 Comparative figure**

The Special Purpose Report and Financial Statements provide comparative figures on the financial year for a period of five months and the amounts presented are not entirely comparable due to the difference in duration of the current period and the comparative period.

**26 Approval of Special Purpose Report and Financial Statements**

The Special Purpose Report and Financial Statements were approved by the Centre's Officials on.....

27 ANALYSIS OF EXPENSES BY NATURE AND FUNCTION  
FOR THE YEAR ENDED 31 DECEMBER, 2021.

31/12/2021  
(12 months)

	WORLD BANK	NIH	BBSRC	JWARG	H3 AFRICA	CEPI-BIO	PHA4GE	ASLM	WARN-ID	AAS	ROCKERFELLER-UG	CAMBRIDGE	EID032	CAMRA	BMGE	WELLCOME	AUDACIOUS	CEPI EPI	FASTGRANT	TOTAL
	=N=	=N=	=N=	=N=	=N=	=N=	=N=	=N=	=N=	=N=	=N=	=N=	=N=	=N=	=N=	=N=	=N=	=N=	=N=	=N=
Salaries and Wages	6,690,000	-	-	62,943,000	29,907,263	26,251,749	5,124,933	4,107,200	-	-	2,500,000	30,000	94,303,260	-	-	55,196,575	549,264,057	-	47,687,100	884,005,136
Seminars and Conferences - Academic	807,419	2,937,330	-	346,000	-	-	-	-	-	-	-	-	-	-	-	-	528,140	-	-	4,618,889
Printing and Stationery	5,517,601	-	-	1,805,568	5,500	-	-	-	-	-	-	-	623,000	-	-	3,200	1,183,176	-	-	9,138,046
Public Relations/Publicity	35,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	35,000
Internet Connectivity Expenses	71,000	-	-	331,900	63,900	-	615,000	-	-	-	-	-	-	-	-	-	2,250,000	-	-	3,331,800
I.T Expenses	194,017	-	-	6,913,500	68,264	446,000	1,167,621	-	-	-	-	-	-	-	-	-	2,956,940	-	-	11,746,342
Cleaning Expenses	2,388,889	-	-	309,920	213,320	-	-	-	-	-	-	-	-	-	-	13,040	43,050	-	-	2,968,219
Electricity & Lighting	443,900	-	-	429,900	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	873,800
Telephone Expenses	204,150	-	-	229,600	2,393,855	-	-	-	-	-	-	4,000	-	-	-	-	2,200	-	-	2,833,805
Transport & Travelling	1,368,400	-	-	2,586,075	99,450	-	-	-	-	-	187,000	454,002	-	-	-	70,300	228,050	-	-	4,993,277
Rent Expenses	40,000	-	-	1,412,667	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,452,667
Postage Expenses	51,975	-	-	8,000	83,490	-	-	-	-	-	-	-	-	-	-	-	217,082	-	-	360,547
Entertainment	778,153	-	-	233,330	4,600	-	-	-	-	-	652,260	-	-	-	-	48,340	214,130	-	-	1,930,813
Subscriptions & Licences	-	-	-	38,000	216,065	-	92,130	-	-	-	-	-	-	-	-	-	1,704,151	-	-	2,050,345
Bank Charges	344,719	1,469	2,019	273,772	660,583	56,000	25,762	11,946	2,114	2,114	75,460	2,598	726,547	34,690	8,883	306,453	5,401,171	4	98,887	8,035,190
Hotel Expenses	2,448,110	-	-	3,431,587	1,039,119	-	-	-	-	-	-	72,000	120,000	-	-	244,000	2,833,659	-	-	10,188,475
Gift & Donation Expenses	5,820,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	40,000	-	-	5,860,000
Other Conference & Airfare Expenses	245,870	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	245,870
External Auditor Expenses	500,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	500,000
Covid-19 Test Expenses	2,457,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	273,400	-	-	2,730,400
Sample - Transport	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	120,000	-	-	120,000
Repair & Maint. - Motor Vehicles	246,225	-	-	1,238,360	15,000	150,000	-	-	-	-	-	-	125,000	-	-	-	3,138,740	-	-	4,913,325
Repair & Maint. - Furniture & Fittings	699,750	-	-	1,979,420	5,800	-	-	-	-	-	-	-	-	-	-	26,500	945,500	-	-	3,656,970
Repair & Maint. - Equipments	1,295,823	-	-	1,957,825	-	-	-	-	-	-	-	-	-	-	-	42,500	786,337	-	-	4,082,485
Repair & Maint. Buildings - University Buildings	180,430	-	-	10,000	-	-	-	-	-	-	-	-	-	-	-	-	8,500	-	-	198,930
Repair & Maint. - Generator	1,832,399	-	-	426,100	4,500	988,000	-	-	-	-	-	-	-	-	-	-	-	-	-	3,250,999
Repair & Maint. - Office Equipment	-	-	-	675,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	675,000
Motor Vehicle Running	2,540,320	-	-	2,003,461	653,306	-	-	-	-	-	18,100	5,000	-	-	-	155,831	2,095,690	-	-	7,471,708
Generator Running Expenses	5,880,000	-	-	2,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	5,882,000
Other Medical Expenses	67,950	-	-	-	30,000	-	-	-	-	-	-	-	-	-	-	-	475,392	-	-	573,342
ACEGID: Lab. Consumables	6,907,193	-	-	35,495,249	4,727,728	-	-	-	-	-	26,827,780	13,000	103,691,013	-	-	7,503,759	995,016,242	-	-	1,180,181,964
Exchange Rate Variance	-	-	-	-	-	-	-	-	-	-	-	96,940	-	-	-	654,575	-	-	-	751,515
Depreciation - Motor Vehicles	33,738,388	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	33,738,388
Depreciation - Plant & Machinery	1,318,560	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,318,560
Depreciation - I.T Equipment	8,446,421	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	8,446,421
Depreciation - Office & Household Equip.	4,721,985	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	4,721,985
Depreciation - Laboratory Equipment	182,854,210	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	182,854,210
Depreciation - Fur. & Fittings	18,841,171	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	18,841,171
Depreciation - Generators	5,961,455	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	5,961,455
Depreciation - Guest House Equipment	280,518	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	280,518
Depreciation - Building Improvement	1,765,662	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,765,662
Depreciation - ACEGID Software	4,309,384	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	4,309,384
Facilities & Administrative Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	198,749,461	-	-	198,749,461
Subaward	-	-	-	-	177,329,221	-	-	-	-	-	-	-	-	7,613,662	-	4,436,355	-	-	-	189,379,238
Genomics Foundational Training Exp.	1,129,458	-	-	8,127,857	2,296,894	-	1,236,950	3,686,540	-	-	-	-	-	-	-	-	-	-	-	16,477,698
Africa Centre of Excellence Meeting & Workshop	800,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	800,000
Publication in Journals	-	-	-	1,751,127	4,149,625	-	-	-	-	-	-	-	-	-	-	-	489,544	-	-	6,390,296
Air Fare	1,714,978	-	-	251,382	5,681,347	-	-	-	-	-	190,764	-	-	-	-	424,000	8,290,260	-	-	16,552,731
Per Diem	682,000	-	-	1,429,000	3,314,446	-	-	-	-	-	442,000	60,000	200,000	797,088	-	586,000	9,192,973	-	-	16,703,506
Project Vehicle Leasing	-	-	-	32,772,800	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	32,772,800
Other Research Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	28,340,103	-	-	-	28,340,103
<b>TOTAL</b>	<b>316,620,482</b>	<b>2,938,799</b>	<b>2,019</b>	<b>169,412,399</b>	<b>232,963,277</b>	<b>27,891,748</b>	<b>8,262,395</b>	<b>7,805,686</b>	<b>2,114</b>	<b>2,114</b>	<b>30,893,364</b>	<b>737,539</b>	<b>199,788,820</b>	<b>8,445,440</b>	<b>8,883</b>	<b>98,051,531</b>	<b>1,786,447,842</b>	<b>4</b>	<b>47,785,987</b>	<b>2,938,060,445</b>



**AFRICAN CENTRE OF EXCELLENCE FOR GENOMICS OF INFECTIOUS DISEASES (ACEGID)**  
**Special Purpose Report and Financial Statements for the Year Ended 31 December, 2021**

**28 ANALYSIS OF EXPENSES BY NATURE AND FUNCTION**  
**FOR THE PERIOD ENDED 31 DECEMBER, 2020.**

	WORLD BANK	CEPI-BIO	BBSRC	JWARG	H3 AFRICA	AUDACIOUS	WELCOME	CEPI-EPI	NIH	FASTGRANT	31/12/2020 (5 months) TOTAL
	=N=	=N=	=N=	=N=	=N=	=N=	=N=	=N=	=N=	=N=	=N=
Salaries & Wages	1,711,900	5,955,743	8,961,880	4,051,013	10,845,833	267,700,246	14,126,835	-	-	22,770,000	336,123,450
Publication in Journal	-	-	-	-	872,748	453,502	-	-	-	-	1,326,250
Seminars and Training	142,999	-	-	-	37,950	1,741,470	-	-	-	-	1,922,419
Per Diem	137,000	-	-	-	-	1,587,402	-	-	-	-	1,724,402
Printing and Stationery	1,740,790	1,837	4,930	136,163	-	-	2,580	-	-	-	1,886,300
Other Conference and Air Fare	-	-	-	-	3,855,638	1,508,010	-	-	-	-	5,363,648
Postages	71,743	-	-	-	-	-	4,000	-	-	-	75,743
Other IT Expenses	325,020	-	-	-	20,100	1,061,400	-	-	-	-	1,406,520
Cleaning	847,730	-	2,050	-	-	-	78,950	-	-	-	928,730
Subscription	-	-	-	-	-	7,590,000	-	-	-	-	7,590,000
Electricity & Lighting	50,000	-	-	-	-	-	-	-	-	-	50,000
Telephone	78,300	-	2,200	-	948,750	-	-	-	-	-	1,029,250
Transport & Travelling	191,329	-	-	-	-	183,300	-	-	-	-	374,629
Entertainment	1,621,290	-	55,500	-	-	44,400	39,500	-	-	-	1,760,690
Bank Charges	2,661,797	20,415	18,541	22,317	676,512	-	25,595	-	-	53,039	3,478,216
Insurance Expenses	242,946	-	-	-	-	-	-	-	-	-	242,946
Hotel Expenses	358,400	-	-	-	-	174,919	400,000	-	-	-	933,319
Rent Expenses	500,000	-	-	-	-	-	-	-	-	-	500,000
Office Consumables	13,600	-	-	-	-	-	-	-	-	-	13,600
External Auditor Expenses	388,750	-	-	-	-	-	-	-	-	-	388,750
Covid-19 Test Expenses	618,000	-	-	-	-	-	-	-	-	-	618,000
Repairs & Maintenance - Motor Vehicles	195,425	-	19,820	-	1,525,450	715,425	13,700	-	-	-	2,469,820
Repairs & Maintenance - Furnitures & Fittings	78,200	-	-	-	-	-	800	-	-	-	79,000
Repairs & Maintenance - Equipment	733,434	-	-	129,000	-	1,170,587	37,918	-	-	-	2,070,939
Repairs & Maintenance - Generators	1,086,183	-	-	117,970	-	-	-	-	-	-	1,204,153
Project Vehicle leasing	-	-	-	24,288,000	-	-	-	-	-	-	24,288,000
Motor Vehicle Running	539,932	-	3,000	-	335,863	569,735	92,906	-	-	-	1,541,436
Generators Running	920,000	-	-	-	-	-	-	-	-	-	920,000
Lab. Consumables	3,625,964	-	157,499	-	4,150	308,107,315	240,650	-	-	-	312,135,578
Depreciation	81,844,691	-	-	-	-	-	-	-	-	-	81,844,691
Facilities & Administrative	-	-	-	7,982,403	-	-	-	-	-	7,590,000	15,572,403
Subaward	-	-	-	-	110,437,119	94,875,000	-	-	-	-	205,312,119
<b>TOTAL</b>	<b>100,725,365</b>	<b>5,997,995</b>	<b>9,225,420</b>	<b>36,726,866</b>	<b>129,560,113</b>	<b>687,482,711</b>	<b>15,063,434</b>	<b>-</b>	<b>-</b>	<b>30,413,039</b>	<b>1,015,175,000</b>

## OTHER NATIONAL DISCLOSURES



**AFRICAN CENTRE OF EXCELLENCE FOR GENOMICS OF INFECTIOUS DISEASES (ACEGID)**  
**Special Purpose Report and Financial Statements for the Year Ended 31 December, 2021**

**STATEMENT OF VALUE ADDED**

**FOR THE YEAR ENDED 31 DECEMBER, 2021**

	31/12/2021 (12 months) 2021 =N=	%	31/12/2020 (5 months) 2020 =N=	%
Grants	3,813,607,170		1,092,181,395	
Interest Received	460,255		61,218	
Exchange Gains & Other Income	2,278,510,571		329,835,345	
	<u>6,092,577,996</u>		<u>1,422,077,958</u>	
Cost of materials and services				
Local	(358,363,511)		(79,759,162)	
Foreign	(1,433,454,045)		(517,447,697)	
<b>Value Added</b>	<u><u>4,300,760,440</u></u>	<u>100</u>	<u><u>824,871,099</u></u>	<u>100</u>
<b>Applied as follows:</b>				
<b>To pay Employees</b>				
Salaries and Wages	884,005,136	21	336,123,450	41
<b>To pay Government</b>				
Tax Expenses	-		-	
<b>For Future Expansion</b>				
Depreciation - PPE	257,928,370	6	80,421,966	10
Amortization - Intangible Assets	4,309,384	0	1,422,725	0
Excess of Income over Expenditure - Surplus	3,154,517,550	73	406,902,958	49
<b>Value Added</b>	<u><u>4,300,760,440</u></u>	<u>100</u>	<u><u>824,871,099</u></u>	<u>100</u>

Value added represents the additional wealth which the Centre has been able to create by its own and its employees' efforts.

This statement shows the allocation of that wealth to employees and the amount retained for future creation of more wealth.

AFRICAN CENTRE OF EXCELLENCE FOR GENOMICS OF INFECTIOUS DISEASES (ACEGID)

Special Purpose Report and Financial Statements for the Year Ended 31 December, 2021

FINANCIAL SUMMARY

AS AT 31 DECEMBER 2021

	31/12/2021 (12 months) =N=	31/12/2020 (5 months) =N=	31/07/2020 (4 months) =N=	31/03/2020 (15 months) =N=	31/12/2018 (12 months) =N=
<b>STATEMENT OF FINANCIAL POSITION</b>					
Non-Current Assets	3,306,786,018	2,475,685,245	1,666,008,721	1,744,863,919	849,950,811
Current Assets	5,787,596,648	3,305,568,836	1,058,668,422	1,278,551,748	990,865,615
<b>TOTAL ASSETS</b>	<b>9,094,382,666</b>	<b>5,781,254,081</b>	<b>2,724,677,143</b>	<b>3,023,415,668</b>	<b>1,840,816,426</b>
<b>RESERVES AND LIABILITIES:</b>					
Reserves	8,036,011,266	4,881,493,716	2,253,711,399	2,473,869,693	1,819,924,449
<b>CURRENT LIABILITIES</b>					
Other Payables	1,058,371,400	899,760,365	470,965,744	549,545,975	20,891,977
	<b>9,094,382,666</b>	<b>5,781,254,081</b>	<b>2,724,677,143</b>	<b>3,023,415,668</b>	<b>1,840,816,426</b>
<b>STATEMENT OF INCOME AND EXPENDITURE</b>					
Grants and Other Income	6,092,577,996	1,422,077,958	516,022,862	1,596,306,854	1,535,724,355
Expenditure for the year	(2,938,060,446)	(1,015,175,000)	(237,880,883)	(942,361,610)	(695,164,957)
Surplus for the year	<b>3,154,517,550</b>	<b>406,902,958</b>	<b>278,141,979</b>	<b>653,945,244</b>	<b>840,559,398</b>